

# Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical devices: clinical significance and implications for decision making—a position paper of the European Heart Rhythm Association endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society

**Giuseppe Boriani (Chair, Italy)\*, Irina Savelieva (Co-chair, UK), Gheorghe-Andrei Dan (Romania), Jean Claude Deharo (France), Charles Ferro (UK), Carsten W. Israel (Germany), Deirdre A. Lane (UK), Gaetano La Manna (Italy), Joseph Morton (Australia), Angel Moya Mitjans (Spain), Marc A. Vos (The Netherlands), Mintu P. Turakhia (USA), and Gregory Y.H. Lip (UK)**

**Document reviewers: Bulent Gorenek (Review Coordinator, Turkey), Yoshihide Takahashi (Japan), Dennis Lau (Australia), Mina Chung (USA), Jens Cosedis Nielsen (Denmark), Laurent Fauchier (France), Tatjana Potpara (Serbia), Francisco Marin (Spain), Gulmira Kudaiberdieva (Turkey), Gerhard Hindricks (Germany), Cecilia Linde (Sweden), and Michele Brignole (Italy)**

Online publish-ahead-of-print 24 June 2015

## Keywords

Arrhythmias • Atrial fibrillation • Ventricular tachyarrhythmias • Epidemiology • Chronic kidney disease • Dialysis • Hemodialysis • Drugs • Cardiac implantable electrical devices • Cardiac resynchronization therapy • Infection • Implantable cardioverter defibrillator • Pacemaker • Sudden cardiac death

## Table of Contents

Introduction . . . . .	1170	Changes in drug pharmacokinetics in chronic kidney disease with specific focus on antiarrhythmic agents, beta-blockers, and antithrombotic drugs . . . . .	1174
How to stage chronic kidney disease and how to monitor the impairment in renal function? . . . . .	1171	Risk of thromboembolic events and risk of bleeding in atrial fibrillation . . . . .	1176
Epidemiology of chronic kidney disease and its relationships to hypertension, heart failure, and atrial fibrillation . . . . .	1172	Association with other co-morbidities (hypertension, chronic obstructive pulmonary disease, etc.) . . . . .	1182
Progression of chronic kidney disease and impact on patients' outcome . . . . .	1172	Contrast-induced acute kidney injury (see Supplementary material online) . . . . .	1182
Implications of chronic kidney disease in the management of a patient with arrhythmias . . . . .	1173	Implications of arrhythmias in the management of a patient with chronic kidney disease . . . . .	1182
Arrhythmogenesis in chronic kidney disease: electrolyte disturbances, modulation of arrhythmia mechanisms, and fibrosis . . . . .	1173	Ventricular tachyarrhythmias and sudden death in advanced chronic kidney disease and in patients treated with haemodialysis . . . . .	1182

\* Corresponding author. Giuseppe Boriani, Institute of Cardiology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, S.Orsola-Malpighi University Hospital, Via Massarenti 9, 40138 Bologna, Italy. Tel: +39 051 349858; fax: +39 051 344859. E-mail address: giuseppe.boriani@unibo.it  
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2015. For permissions please email: journals.permissions@oup.com.

Atrial fibrillation and supraventricular tachyarrhythmias in advanced chronic kidney disease and in the chronic kidney disease patient treated with haemodialysis: haemodynamic effects and acute and long-term treatments . . . . . 1183

Antiarrhythmics, beta-blockers, antithrombotics, and dialysis (see Supplementary material online). . . . . 1183

Implications of arrhythmias in the perioperative management of a patient with chronic kidney disease . . . . . 1184

Implications of chronic kidney disease in the management of a patient with an implantable electrical device . . . . . 1184

Impact of chronic kidney disease on indication to treatment and patients' outcomes . . . . . 1184

    Pacing for bradycardia. . . . . 1184

    Cardiac resynchronization therapy for heart failure . . . . . 1185

    Implantable cardioverter-defibrillator for sudden death . . . . . 1185

Risk of infections and management . . . . . 1185

Risk of syncope (see Supplementary material online) . . . . . 1188

Pregnancy (see Supplementary material online) . . . . . 1188

Life expectancy (see Supplementary material online) . . . . . 1188

Implications of an implantable electrical device on the management of a patient with chronic kidney disease . . . . . 1188

    Perioperative management for electromagnetic interferences . . . . . 1188

    Management for magnetic resonance imaging scanning . . . . . 1189

    End-of-life issues (see Supplementary material online). . . . . 1189

The costs of chronic kidney disease and related organizational issues . . . . . 1189

Areas for further research . . . . . 1190

Consensus statements . . . . . 1190


References . . . . . 1191

## Introduction

The kidney exerts multiple functions, and pathophysiological interactions between the kidney and the heart have important clinical implications, but it has only recently become clear that these interactions should be studied across the whole spectrum of reduced kidney function and not only in cases with severe, end-stage renal disease (ESRD), as has been done for many years.<sup>1</sup> The prevalence of chronic kidney disease (CKD), defined as a glomerular filtration rate (GFR) of < 60 mL/min/1.73 m<sup>2</sup> for > 3 months, exceeds 10% in the adult population and reaches 47% in subjects older than 70 years, according to data from the USA, with a trend towards a recent increasing prevalence.<sup>1,2</sup>

Many interactions between kidney and cardiovascular functions have important implications for clinical management and health policy (Figure 1), since even mild forms of kidney disease are associated with an increased risk of cardiovascular morbidity and overall mortality, and renal function may worsen over time.<sup>1,3</sup>

Although cardiovascular disease (CVD) and cardiac disorders are more frequent and severe in CKD, they are often not recognized, or undertreated, in view of the complexity of patient management in this setting.<sup>4</sup> On the other hand, the presence and evolution of CKD is often not evaluated and monitored in patients with various forms of heart diseases, including patients with cardiac rhythm disturbances, a setting where CKD is associated with challenging decision-making on the management of specific treatments and interventions. In patients with cardiac diseases, CKD predisposes to acute kidney injury and vice versa, and



**Figure 1** Stages of the development and progression of chronic kidney disease (CKD), including complications and strategies to improve outcomes. Modified from Eckardt et al.<sup>1</sup> GFR, glomerular filtration rate.

both may strongly influence clinical management of cardiac conditions.

Considering the need for increasing the awareness of CKD among the cardiologists, with specific focus on those dedicated to management of arrhythmic disorders, as well as the need to create the basis for collaborative, personalized, patient-centred care, with integration of different healthcare specialists, the European Heart Rhythm Association (EHRA), in collaboration with Heart Rhythm Society (HRS) and Asian Pacific Heart Rhythm Society (APHRS), has promoted the present document, resulting from an interaction between cardiologists and nephrologists.

## How to stage chronic kidney disease and how to monitor the impairment in renal function?

Chronic kidney disease is defined as the presence of kidney abnormalities, which can involve its structure and/or its function, for a period of longer than 3 months, with implications for health.<sup>5</sup> This definition incorporates both a measure of chronicity as well as the concept that a variety of abnormalities of kidney structure or function may exist; not all may have implications for the health of the individual and therefore need to be taken in context.

The kidney has many functions, including excretory, metabolic, and endocrine. The GFR is the only one component of excretory function, but is widely accepted as the best overall index of kidney function, because it is generally reduced after widespread structural damage and most other kidney function declines in parallel with GFR.<sup>5</sup>

The GFR can be estimated from the serum creatinine using a number of equations to give an estimated GFR (eGFR).<sup>5</sup> Supplementary material online, *Table S1* summarizes the equations proposed for eGFR.

The Cockcroft–Gault equation was proposed around 40 years ago,<sup>6</sup> but has a series of bias in patients with a higher body weight or BMI, and its overall accuracy is lower than that of the two other formulas for eGFR described below.<sup>7</sup>

The Modification of Diet in Renal Disease (MDRD)<sup>8</sup> equation uses four variables (age, gender, serum creatinine, and ethnicity) to calculate eGFR and is one of the most widely used and routinely reported by laboratories globally.

The chronic kidney disease epidemiology collaboration equation (CKD-EPI) equation<sup>9</sup> uses the same four variables as the MDRD equation and is becoming more widely adopted.<sup>5</sup> The CKD-EPI equation has a less bias than the MDRD study equation, especially at GFR >60 mL/min/1.73 m<sup>2</sup>, a small improvement in precision and greater accuracy.<sup>10</sup> The clinician should remain aware of caveats for any estimating equation, which may influence the accuracy in a given individual patient and consider using additional tests (such as cystatin C or a clearance measurement) for confirmatory testing in specific circumstances when eGFR based on serum creatinine is less accurate.<sup>5,9</sup> For example, in chronic heart failure, cystatin C may be a more sensitive marker of impaired GFR compared with creatinine partly due to the loss of muscle mass associated with this condition.<sup>11</sup>

The current recommended staging of CKD is based on a classification encompassing cause and severity, as expressed by the level of GFR and the level of albuminuria (Cause, GFR, and Albuminuria referred to as CGA staging: *Table 1*; 5 KDIGO). A threshold GFR of <60 mL/min/1.73 m<sup>2</sup> (GFR categories G3a–G5) for >3 months is used to indicate CKD as this is less than half of the normal value in young adults of 125 mL/min/1.73 m<sup>2</sup>.<sup>5</sup> Albuminuria is included as an additional marker of severity of injury, because albuminuria itself is strongly associated not only with progression of CKD but also with adverse, mainly cardiovascular, prognosis.<sup>12–14</sup> Albuminuria detection is recommended in patients with cardiac disease and the appropriate tests, in order of preference, are urinary albumin, reported as a ratio of urinary creatinine (albumin-to-creatinine ratio), a timed urine collection for urinary albumin, urine protein-to-creatinine ratio, and reagent strip point-of-care urinalysis.<sup>5</sup>

The presence of CKD should be monitored over time: renal function and albuminuria should be repeated at least once a year but more frequently if the patient has a high risk of progression and/or where measurement will impact therapeutic decisions.<sup>5</sup> Progression

**Table 1** Staging of chronic kidney disease according to the CGA approach (Cause, Glomerular Filtration, and Albuminuria)

Cause of CKD	GFR categories (mL/min/1.73 m <sup>2</sup> )	Albuminuria categories
Presence or absence of systemic disease	G1: ≥90 (normal or high)	ACR (mg/g): A1 <30 (normal or mildly increased) A2 30–300 (moderately increased) A3 >300 (severely increased)
Location within the kidney of pathological–anatomical findings (glomerular, tubulointerstitial, vascular, cystic, and congenital diseases)	G2: 60–89 (mildly decreased)  G3a: 45–59 (mildly to moderately decreased) G3b: 30–44 (moderately to severely decreased) G4: 15–29 (severely decreased) G5: <15 [kidney failure (includes ESRD)]	ACR (mg/mmol): A1: <3 (normal or mildly increased) A2: 3–30 (moderately increased) A3: >300 (severely increased) AER (mg/24 h): A1: <30 (normal or mildly increased) A2: 30–300 (moderately increased) A3: >300 (severely increased)

CKD, chronic kidney disease; ESRD, end-stage renal disease; GFR, glomerular filtration rate; ACR, albumin-to-creatinine ratio; AER, albumin excretion rate.

of CKD is based on a decline in GFR category, recognizing that small fluctuations in GFR are common and are not necessarily indicative of progression.<sup>5</sup> Rapid progression is currently defined as a sustained decline in eGFR of  $>5$  mL/min/1.73 m<sup>2</sup>/year. In patients with CKD progression, current management should be reviewed and potentially reversible causes of progression assessed. Consideration should also be given to a specialist referral.

## Epidemiology of chronic kidney disease and its relationships to hypertension, heart failure, and atrial fibrillation

There is growing global awareness and recognition of early CKD as a public health problem since the introduction of a clearer, multi-layered definition of the condition based on GFR initially proposed by the National Kidney Foundation Kidney Disease Outcome Quality Initiative in 2002<sup>15</sup> and subsequently updated in the KDIGO clinical practice guidelines.<sup>5,16</sup>

Data from the National Health and Nutrition Examination Surveys in the USA suggest that the prevalence of moderately reduced GFR (30–59 mL/min/1.73 m<sup>2</sup>) significantly increased in 1999–2004, as compared to 1988–1994, from 5.4 to 7.7%, and also the prevalence of severely reduced GFR (15–29 mL/min/1.73 m<sup>2</sup>) significantly increased from 0.21 to 0.35%.<sup>17</sup> Most of the increase can be explained by the increasing prevalence of hypertension and diabetes.<sup>17</sup> Other countries suggest a similar prevalence with marked increases in older age groups.<sup>17–24</sup>

Chronic kidney disease and CVDs share many common risk factors such as hypertension, diabetes, and age. Epidemiological studies and surveys show an age-associated GFR decline, observed in both longitudinal and cross-sectional studies, although with substantial variability among individuals within the population.<sup>5</sup> Chronic kidney disease is an independent risk factor for cardiovascular morbidity and mortality, with an inverse graded relationship with GFRs  $<60$  mL/min/1.73 m<sup>2</sup>,<sup>12,25</sup> and perhaps  $<90$  mL/min/1.73 m<sup>2</sup>,<sup>26</sup> independent of other risk factors. Although cardiovascular risk in ESRD is extreme,<sup>27,28</sup> the public health burden of CVD caused by early-stage CKD is much greater.<sup>29</sup> In a recent meta-analysis of the relationship between eGFR and cardiovascular risk, a 30% lower GFR was consistently associated with a 20–30% higher risk of major vascular events and all-cause mortality.<sup>30</sup> If causal, this would imply that up to 10% of vascular events in middle age and 20% in old age might be attributable to reduced renal function. The phenotype of CVD associated with CKD is multifactorial with arterial stiffening causing heart failure, stroke, arrhythmic sudden death, and premature atherosclerosis causing vascular occlusive events.<sup>31,32</sup>

A strong, independent and graded relationship also exists between the degree of albuminuria and cardiovascular risk.<sup>12</sup> Cardiovascular risk is increased even within currently defined normal levels of albuminuria and below those that can be detected by a standard urinary dipstick.<sup>12</sup> Albuminuria, together with eGFR, exerted a multiplicative effect on the risks of all-cause and cardiovascular mortality.

There is a close relationship between the heart and kidney with accumulating evidence that dysfunction of one organ negatively affects the other, the so-called Cardio-Renal Syndrome (CRS).<sup>33–35</sup> Acute heart failure leading to CKD is defined as type 1 CRS, chronic heart failure leading to CKD as type 2 CRS, acute kidney disease leading to an acute cardiac disorder (e.g. arrhythmia, heart failure, cardiac ischaemic event, etc.) as type 3 CRS, and CKD leading to cardiac problems and adverse cardiac events as type 4 CRS, whereas type 5 CRS refers to a systemic condition (e.g. sepsis) causing both cardiac and renal dysfunction.

Observational data show that heart failure and CKD commonly coexist with CKD documented in 26–63% of heart failure patients,<sup>36–38</sup> but cannot determine which of the two disease processes was primary vs. secondary.<sup>34</sup> The close relationship between CKD and heart failure is also demonstrated in other cardiovascular conditions. Approximately 30% of patients with hypertension will have CKD, whereas nearly 90% of patients with CKD will also be hypertensive.<sup>39</sup> Similarly, the prevalence of atrial fibrillation (AF) in the general population is  $\sim 1$ –2% and increases markedly with age,<sup>40–44</sup> and  $\sim 11$ –23% of patients with AF will have CKD.<sup>40,44–47</sup>

Having CKD is associated with an increased risk of subsequently developing AF and vice versa.<sup>48</sup> The prevalence of AF in patients on dialysis is high with estimates ranging from 7 to 27% and also increases with age.<sup>49</sup> However, the relative risk is much higher in the young.<sup>49</sup> Among dialysis patients aged  $>65$ , the incidence of AF is quite high (15%) and incidence and prevalence have both steadily increased since 1995.<sup>50,51</sup> Fortunately, mortality and stroke incidence after the development of AF in this population has continued to decline.<sup>50</sup> The prevalence of AF in the pre-dialysis CKD population appears to be similar to that of the dialysis population at 4–21%.<sup>52–55</sup> Chronic kidney disease is also present in a substantial proportion of patients with acute coronary syndromes; indeed, large registries report that almost 40% of patients with non-ST-elevation myocardial infarction and 30% of those with ST-elevation myocardial infarction have significant renal impairment, with GFR  $<60$  mL/min/1.73 m<sup>2</sup>.<sup>56,57</sup>

## Progression of chronic kidney disease and impact on patients' outcomes

Reduced glomerular filtration and proteinuria have repeatedly been shown to increase risk of cardiovascular events across a spectrum of cardiovascular risk profiles.<sup>12,58–60</sup> Death from CVD is a common cause of death patients with progression of CKD. The increase in cardiovascular risk is generally proportional due to the severity of CKD, which is due to a combination of the independent risk attributable to CKD as well as the increased prevalence of other cardiovascular risk factors, such as diabetes and hypertension, in advanced CKD.

Patients with less severe CKD are more likely to die of CVD than to develop kidney failure.<sup>58,61</sup> The cause of death is most commonly linked to CVD, as incident coronary heart disease is quite common.<sup>62</sup> In a study of 28 000 patients with GFR  $\leq 90$  mL/min from a single healthcare system in the USA, the 5-year rate of renal replacement therapy for CKD stages 2, 3, and 4 was 1.1, 1.3, and

19.9%, respectively, whereas the mortality rate was 19.5, 24.3, and 45.7%.<sup>27</sup> Congestive heart failure, coronary disease, and diabetes were more prevalent in patients who died. However, younger patients with significant proteinuria, more localized kidney disease, and an absence of other cardiovascular risk factors are more likely to progress to renal replacement therapy prior due to a lower competing risk of cardiovascular death.<sup>63</sup>

Clinical predictors of accelerated progression may therefore also predict the development of cardiovascular sequelae. Multivariate analyses from a number of observational studies have defined clinical predictors of accelerated GFR decline, including more severe proteinuria, higher blood pressure, lower serum high-density lipoprotein, black ethnicity, smoking, physical inactivity, and obesity.<sup>64–66</sup> More recently, a model including age, sex, eGFR, and laboratory tests commonly performed in CKD patients (albuminuria, serum calcium, serum phosphate, serum bicarbonate, and serum albumin) predicted CKD progression with high discrimination (C-statistic 0.917 in derivation and 0.841 in validation).<sup>67</sup>

Atrial fibrillation has been shown to accelerate CKD progression. In a regional US healthcare system study of 206 229 patients with GFR <60 mL/min, incident AF increased the risk of progression to ESRD (HR 1.67).<sup>68</sup> Such modification of progression by AF has been demonstrated even in relatively preserved function with no dipstick-detectable proteinuria.<sup>48</sup> More recent observational data suggest that anticoagulation in AF could be associated with a slowing of CKD progression.<sup>69,70</sup> Therefore, treatment of secondary factors associated with CKD progression, which may include CVDs themselves, could favourably reduce the cumulative risk of cardiovascular morbidity and mortality.

## Implications of chronic kidney disease in the management of a patient with arrhythmias

### Arrhythmogenesis in chronic kidney disease: electrolyte disturbances, modulation of arrhythmia mechanisms, and fibrosis

The cardio-renal axis is regulated in such a way that a disturbed balance will both result in cardiac and renal remodelling, a process which is highlighted when considering arrhythmias in patients with impaired renal function.

Patients with the various stages of CKD may present a wide spectrum of arrhythmias, including supraventricular tachycardias, and particularly AF, ventricular ectopic beats, sustained 'malignant' ventricular tachyarrhythmias, and sudden cardiac death (SCD).<sup>71</sup> In more advanced stages, bradyarrhythmias and asystole may also occur, usually associated with hyperkalaemia or other electrolyte derangements.<sup>71</sup>

Ventricular tachyarrhythmias may lead to SCD, but the nature and risk of SCD in dialysis patients remain obscure, although a link with progressive coronary artery disease and myocardial ischaemia has been established. Cardiac arrest after acute myocardial infarction is twice as common in patients on dialysis compared with those with normal renal function.<sup>72</sup> The pathological processes that cause

coronary artery disease are also likely involved in CKD: hyperlipidaemia, hypertension, diabetes, acid–base balance, calcium phosphate metabolism, and inflammatory factors. Still, it appears that arrhythmogenesis in CKD patients also has additional contributing factors other than atherosclerosis. In studies on statins, a dissociation was found between the positive effect on major cardiovascular events and the lack of benefit on cardiovascular mortality and SCD.<sup>72,73</sup>

Arrhythmogenesis in patients with CKD is related to many potentially concurring factors, as presented in Table 2. Among these additional factors favouring arrhythmogenesis, some deserve special consideration:

1. *Left ventricular (LV) hypertrophy and fibrosis*: LV hypertrophy and QT-prolongation (acquired long QT) are common among CKD patients. Left ventricular hypertrophy may, in some cases, evolve to heart failure, an important extra contributor to arrhythmias and SCD.<sup>74</sup> Increased amounts of certain uraemic toxins and an imbalance in the activity of parathyroid hormone promote different forms of cardiac fibrosis. Fibrosis not only compromises the contractile performance, but also hampers intercellular coupling, slows conduction, and thereby increases the propensity to develop ventricular arrhythmias.
2. *Autonomic imbalance*: Sympathetic overactivity is present in all stages of CKD and has long-term pro-arrhythmic effects: it increases repolarization heterogeneity and induces hypertrophy and fibrosis.
3. *Rapid fluid and electrolyte shifts*: Fluid and electrolyte shifts during conventional dialysis treatment may trigger AF or ventricular arrhythmias by favouring electrical instability.<sup>71,75</sup> A number of electrolyte disturbances are known for their increased risk for pro-arrhythmia:
  - *Acute or chronic hypokalaemia*: Hypokalaemia evokes both supraventricular and ventricular tachyarrhythmias. In the ventricles, it delays repolarization (an increase in QT interval) in ventricular myocytes, while increasing the automaticity in

**Table 2** Factors involved in arrhythmogenesis in CKD

Electrolyte alterations (chronic and acute)
Autonomic imbalance
Haemodynamic instability during haemodialysis
Prolongation and increased dispersion of ventricular repolarization
Left ventricular hypertrophy
Left ventricular dysfunction
Myocardial fibrosis
Scars due to myocardial infarction
Macro and microvessels angiopathy (atherosclerosis, diabetic microangiopathy, vascular calcification, etc.)
Endothelial dysfunction
Inflammatory processes
Oxidative stress
Acidosis and acidaemia
Anaemia
Uraemic state

- Purkinje fibres (an increase in ventricular ectopy). The appearance of U-waves in the ECG is one of the typical characteristics.
- **Acute or chronic hyperkalaemia:** Hyperkalaemia is associated with changes at the ECG which, in progression, include tall, peaked T waves with a shortened QT interval (initial findings), followed, with progression of the disorder by lengthening of the PR interval and QRS duration, disappearance of the P wave, idioventricular rhythms, and ultimately marked widening of the QRS up to a sine-wave pattern. Pronounced shortening of the action potential duration may favour re-entrant arrhythmias in conditions of slowed conduction.<sup>76</sup> Ventricular standstill with asystolic cardiac arrest can be a terminal event. The progression and severity of ECG changes have no strict correlation with serum potassium concentrations, and changes are more evident if hyperkalaemia has a rapid onset. Hyperkalaemia can also cause a type I Brugada pattern.
  - **Hypocalcaemia:** This condition, frequently seen in chronic renal insufficiency, is able to decrease contractility and to increase excitability. It appears most frequently in combination with other electrolyte abnormalities.
  - **Hyperphosphataemia:** It is characteristic of ESRD, and may facilitate ventricular tachyarrhythmias and SCD.
  - **Hypo- or hypermagnesaemia:** These electrolyte alterations usually develop in combination with derangements of the other electrolytes and their independent contribution to arrhythmogenesis is uncertain.

## Changes in drug pharmacokinetics in chronic kidney disease with specific focus on antiarrhythmic agents, beta-blockers, and antithrombotic drugs

Pharmacokinetic (PK) studies are not performed routinely in patients with CKD; however, physicians should be aware of the data published in guidelines or provided as summary of product characteristics (SmPC). Potential problems associated with modified PK in CKD patients are:<sup>5</sup>

1. reduced ability to excrete drugs and/or their metabolites,

2. increased sensitivity to medications (e.g. those bound to albumin in hypoalbuminaemic states such as nephritic syndrome),
3. diminished tolerance of side effects, particularly in the elderly, and
4. loss of efficacy

A detailed list of the main alterations of drug PK in CKD patients is summarized in *Table 3*.

Despite several guidelines, there are still controversies regarding the best modality to guide therapeutic decisions of common drugs in patients with CKD.<sup>77</sup> The current guidelines recommend evaluation of GFR when deciding the dose of the drug.<sup>5</sup> Cockcroft–Gault formula, MDRD, or CKD-EPI equations could be used for this purpose each demonstrating virtues and limitations. In the case of drugs with narrow therapeutic ranges (the case of many antiarrhythmic drugs), when precision is desired or in special cases when formula estimate is inaccurate (low muscle mass), direct determination of GFR is required. As recommended by the guidelines,<sup>5</sup> people with CKD should receive, when possible, the same treatment as those with normal renal function. However, the dosages may need adjustment according to GFR, given the implications on prolonged half-life and reduced clearance of the drug, especially for drugs with narrow therapeutic ranges.<sup>77</sup>

The loading dose of a drug is a function of peak concentration desired, volume of distribution, bioavailability (which is 1 for intravenous-administered drugs), and weight. There are no guideline recommended loading doses for antiarrhythmics, beta-blockers, and most antithrombotic drugs. Without a loading dose, maintenance doses will achieve 90% of their steady-state level in 3–4 half lives. The dosage could be adapted in CKD patients through reduction in dose and/or lengthening the dosage interval (more useful with drugs with a longer half-life and a wider therapeutic range).

The main PK characteristics and suggestions for appropriate prescription in CKD patients for most used beta-blockers and antiarrhythmic drugs are described in *Table 4*.<sup>78</sup>

The main PK characteristics for oral anticoagulants and dosing recommendations, in relation with renal function (usually evaluated with the Cockcroft–Gault formula in trials) and according to regulatory approvals, are provided in *Table 5*.<sup>79,80</sup>

**Table 3** Main alterations in drug PK in patients with CKD

PK characteristics	Alterations in CKD
Bioavailability	Decreased absorption (alkaline media, reduced peristalsis, bowel oedema, and phosphate chelation) Altered first pass (decreased biotransformation of parent drug and impaired protein binding resulting in more free drug available for liver)
Volume of distribution	Increased volume of distribution or extracellular volume overload Decreased volume of distribution in muscle wasted patients
Protein binding	Increased or decreased protein binding with a correspondent decrease or increase in free (active) drug concentration Low albumin increases active drug Organic acids accumulate in renal failure and compete with acid drugs for protein binding
Drug metabolism/renal elimination	Drug metabolism could be modified and unpredictable (increased or decreased) Non-renal elimination could be compensatory increased resulting in higher concentrations of potential toxic metabolites Parent compound could accumulate in CKD

**Table 4** Main PK characteristics and suggestions for appropriate prescription in CKD patients for most used beta-blockers and antiarrhythmic drugs (modified from ref. 78)

Drug	PK and elimination	Indications for CKD
Atenolol	About 5% bound to plasma protein; $T_{1/2}$ ~6 h but action duration is 24 h; excreted unchanged in urine	Dose may need to be reduced
Bisoprolol	Approximately 30% bound to protein; peak plasma concentration in 2–4 h; metabolized by the liver but ~50% excreted unchanged in urine	Monitoring; dose may need to be reduced in advanced CKD
Carvedilol	99% protein bound; $T_{1/2}$ ~6–10 h; elimination mainly biliary and 16% urinary	Dosage adjustment usually not required excepting advanced renal failure and elderly
Labetalol	90% protein bound; $T_{1/2}$ ~6–8 h metabolized by liver with inactive metabolites excreted in urine and bile; <5% excreted unchanged in urine	Dose reduction recommended in the elderly
Metoprolol	Approximately 12% protein bound; $T_{1/2}$ ~3–5 h but the effect persists for 12 h; <5% excreted unchanged in urine	No dosage reduction needed
Sotalol	Not protein bound; $T_{1/2}$ ~7–18 h; not metabolized; excreted unchanged in urine (~70%)	Dose to be reduced to one half in CKD and one quarter in severe renal failure where there is relative contraindication in view of the risk of pro-arrhythmic effects
Procainamide	15% protein bound; binds to different tissues; active hepatic metabolite; variable hepatic and renal elimination (60% unchanged); longer elimination in renal failure	Reduction of dose recommended
Quinidine	85% protein bound; 50–90% metabolized by the liver to active metabolites; $T_{1/2}$ ~6 h; 20% excreted in urine	Pro-arrhythmia; could interfere with renal clearance of other drugs
Lidocaine	65% protein bound; 80% rapidly metabolized by the liver to active metabolites; $T_{1/2}$ <2 h; <10% excreted unchanged in urine	No special requirements
Mexiletine	50–70% protein bound; $T_{1/2}$ ~5–17 h; ~15% excreted unchanged in urine	No special requirements
Flecainide	$T_{1/2}$ ~20 h; metabolized by the liver and excreted unchanged in urine (35%)	Dose reduction if GFR <35 mL/min/1.73 m <sup>2</sup>
Propafenone	95% protein bound; metabolized by the liver to active metabolites, excreted in urine (38%); two genetically determined pathways of metabolism (>90% people are rapid metabolizers with $T_{1/2}$ ~2–10 h); <1% excreted unchanged in urine	Careful monitoring recommended (in hospital initiation if advanced CKD)
Vernakalant	25–50% protein bound, extensively and rapidly distributed in the body after intravenous administration, not extensively bound to plasma proteins. Mainly eliminated by the liver with $T_{1/2}$ ~3–5.5 h	Available for intravenous administration at the dose of 3.0 mg/kg followed by 2.0 mg/kg if required
Amiodarone	99% protein bound; widely distributed to different tissues; metabolized by the liver to two active metabolites; no renal elimination	No dosage requirements; not dialyzable; many drug-to-drug interactions
Dronedaron	~98% protein bound; metabolized by the liver to active and inactive metabolites; $T_{1/2}$ ~13–19 h; 6% excreted in urine	No dosage adaptation required in mild and severe renal failure
Dofetilide	High (>90%) bioavailability; protein binding of 60–70%; 80% excreted by the kidney, as unchanged dofetilide (80%) or as inactive or minimally active metabolites (20%); $T_{1/2}$ ~10 h	Dose individualized on the basis of GFR; contraindicated if GFR <20 mL/min
Diltiazem	70–80% protein bound; extensive first-pass effect, metabolism in the liver to active metabolites; bioavailability of ~40%; $T_{1/2}$ ~3.5–9 h; only 2–4% unchanged drug excreted in the urine	Use with caution
Verapamil	About 90% protein bound. High first-pass metabolism, Metabolized in the liver to at least 12 inactive metabolites. Bioavailability 10–35%. 70% is excreted in the urine and 16% in faeces. $T_{1/2}$ ~5–12 h	Dose reduction by 25–50% if CrCl <10 mL/min. Not cleared by haemodialysis
Adenosine	Rapid cell uptake and clearance; PK difficult to be studied; not dependent on renal function	No dosage adaptation required
Digoxin	20–30% protein bound; $T_{1/2}$ ~26–45 h; main route of elimination is renal (closely correlated with the GFR) with 25–28% of elimination by non-renal routes	Dosage adaptation is required, with monitoring of serum digoxin levels

**Table 5** Main PK characteristics for oral anticoagulants and dosing recommendations, according to regulatory approvals (modified from refs <sup>79,80</sup>)

	Warfarin	Dabigatran	Apixaban	Edoxaban	Rivaroxaban
Fraction renally excreted of absorbed dose		80%	27%	50%	35%
Bioavailability	95–100%	3–7%	50%	62%	66% without food Almost 100% with food
Fraction renally excreted of administered dose		4%	14%	37%	33%
Approved for CrCl		≥30 mL/min	≥15 mL/min	≥15 mL/min	≥15 mL/min
Dosing recommendation	CrCl ≥30 mL/min: no adjustment	CrCl ≥50 mL/min: no adjustment (i.e. 150 mg b.i.d.)	Serum creatinine ≥1.5 mg/dL: no adjustment (i.e. 5 mg b.i.d.)	60 mg daily for CrCl 50–95 mL/min, 30 mg daily for CrCl 15–50 mL/min, weight ≤60 kg: not recommended for CrCl >95 mL/min	CrCl ≥50 mL/min: no adjustment (i.e. 20 mg qd)
Dosing if CKD	When CrCl <30 mL/min: use lower doses and monitor closely	When CrCl 30–49 mL/min, 150 mg b.i.d. is possible (SmPC) but 110 mg b.i.d. is recommended if high risk of bleeding <sup>79</sup>	CrCl 15–29 mL/min: 2.5 mg b.i.d. Serum creatinine ≥1.5 mg/dL in combination with age of ≥80 years or weight ≤60 kg. (SmPC) or with other factors that increase bleeding risk (e.g. diltiazem): 2.5 mg b.i.d.	60 mg daily for CrCl 50–95 mL/min, 30 mg daily for CrCl 15–50 mL/min, weight ≤60 kg: not recommended for CrCl >95 mL/min	15 mg q.d. when CrCl 15–49 mL/min
Not recommended if		CrCl <30 mL/min	CrCl <15 mL/min	If CrCl >95 mL/min or <15 mL/min	CrCl <15 mL/min

## Risk of thromboembolic events and risk of bleeding in atrial fibrillation

Patients with CKD are at a high risk of developing incident arrhythmias, such as AF. The presence of AF is also associated with a higher risk of ESRD among patients with CKD.<sup>50,68</sup> When AF is present, patients with associated CKD are at a high risk of stroke and thromboembolism, as well as major bleeding, as included in *Tables 6–8*.<sup>55,81–94</sup> Patients with renal replacement therapy, whether dialysis or renal transplantation, are at particularly a high risk of thromboembolism and bleeding.<sup>55,82,89</sup>

With regard to stroke risk *per se*, AF patients with CKD are clearly at higher risk. Also, the addition of renal impairment (with two points), or the presence of proteinuria or reduced creatinine clearance, was proposed to improve a prediction value of the CHADS<sub>2</sub> score for stroke, leading to the R<sub>2</sub>CHADS<sub>2</sub> (Renal dysfunction [doubled], Congestive heart failure, Hypertension, Age >75, Diabetes, previous Stroke [doubled]) in a substudy from the ROCKET-AF (Rivaroxaban Once daily oral direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) trial and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) stroke risk scores.<sup>95,96</sup>

Nonetheless, the limitations of the R<sub>2</sub>CHADS<sub>2</sub> score include its derivation in a selected anticoagulated trial cohort that excluded patients with severe renal impairment (creatinine clearance <30 mL/min), as well as the evidence that some patients at risk of stroke (CHADS<sub>2</sub> score 0–1) were excluded from the ROCKET-AF trial. The R<sub>2</sub>CHADS<sub>2</sub> score is also inferior to the CHA<sub>2</sub>DS<sub>2</sub>-VASc score in predicting stroke and thromboembolism.<sup>97</sup> Also, those classed as a 'low risk' using the ATRIA score are not a 'low risk' with stroke rates >4%/year if assessed by the CHA<sub>2</sub>DS<sub>2</sub>-VASc score and left untreated.<sup>98,99</sup> In multiple 'real-world' non-anticoagulated cohorts including a broad range of renal (dys)function and stroke risk, CKD does not independently add to the risk of stroke, beyond established stroke risk prediction rules, such as the CHA<sub>2</sub>DS<sub>2</sub>-VASc score.<sup>84,87,100</sup> Furthermore, in one trial cohort with a wider range of renal (dys)function and stroke risk, CKD did not significantly add to the stroke prediction value of the CHA<sub>2</sub>DS<sub>2</sub>-VASc score.<sup>88</sup>

However, renal dysfunction may be co-morbidity determining the higher stroke risk among females,<sup>101</sup> and may have implications for optimizing good quality anticoagulation control among patients on vitamin K antagonists (VKA, e.g. warfarin). Thus, renal disease is one component of 'Medical co-morbidities' within the SAME-TT<sub>2</sub>R<sub>2</sub> score (Sex female, Age <60 years, Medical history [more than two co-morbidities], Treatment [interacting drugs, e.g. amiodarone for rhythm control], Tobacco use [doubled], Race [doubled]) that helps prediction of those patients likely to achieve good anticoagulation control, with a high time in therapeutic range (TTR).<sup>102</sup> Indeed, a high TTR is associated with a low risk of thromboembolism and bleeding.<sup>103,104</sup>

Renal impairment also increases the risk of bleeding, and scores one point in the HAS-BLED score<sup>105</sup> for predicting major haemorrhage in patients with AF.

Optimal thromboprophylaxis in patients with AF and end-stage CKD is a controversial area. Patients with haemodialysis on warfarin seem to be at particularly a high risk of serious bleeding, which may



**Table 6 Risk of thromboembolic and bleeding events in AF patients with renal impairment**

Author, year, country	Study population	Definition of renal impairment	ATT therapy	Thromboembolic events	Bleeding events
Providência, 2014 <sup>81</sup>	Meta-analysis 19 studies 379 506 patients AF patients with CKD	Cockcroft–Gault ( $n = 5$ ) MDRD ( $n = 5$ ) CKD-EPI ( $n = 2$ ) Coding	Warfarin, NOACs, aspirin, or none	CKD ↑ TE risk [HR (95% CI) 1.46 (1.20–1.76); $P = 0.0001$ ] End-stage CKD ↑ TE risk [HR (95% CI) 1.83 (1.56–2.14); $P < 0.00001$ ] Warfarin ↓ TE in non-end-stage CKD patients [HR (95% CI) 0.39 (0.18–0.86); $P < 0.00001$ ] NOACs ↓ TE compared with warfarin [HR (95% CI) 0.80 (0.66–0.96); $P = 0.02$ ] and aspirin [HR (95% CI) 0.32 (0.19–0.55); $P < 0.0001$ ] in non-end-stage CKD patients	
Shah, 2014, Canada <sup>82</sup>	Retrospective population-based cohort study Patients aged ≥ 65 years admitted to the hospital with primary/secondary diagnosis of AF from 1998 to 2007	Dialysis: $n = 1626$ Mean (SD) age: 75 (8) years; 634 (39.0%) women Non-dialysis: $n = 204\ 210$ Mean (SD) age: 78 (10); 104 652 (51.2%) women	Warfarin vs. no warfarin OAC: 756 (46.4%) dialysis vs. 103 473 (50.7%) non-dialysis	No. of events (incidence rate per 100 patient-years) Dialysis patients: 107 (3.12) On warfarin vs. off-warfarin: 52 (3.37) vs. 55 (2.91) Non-dialysis patients: 19 489 (2.35) On warfarin vs. off-warfarin: 9241 (2.19) vs. 10 248 (2.51) Warfarin use not associated with ↓ stroke risk in dialysis patients [adjusted HR (95% CI) 1.14 (0.78–1.67)] ↓ Stroke risk with warfarin use in non-dialysis patients [adjusted HR (95% CI) 0.87 (0.85–0.90)]	No. of events (incidence rate per 100 patient-years) Dialysis patients: 275 (8.89) On warfarin vs. off-warfarin: 149 (10.88) vs. 126 (7.31) Non-dialysis patients: 34 035 (4.32) On warfarin vs. off-warfarin: 18 340 (4.64) vs. 15 695 (4.00) Warfarin use ↑ bleeding risk in dialysis [adjusted HR (95% CI) 1.44 (1.13–1.85)] and non-dialysis [HR (95% CI) 1.19 (1.13–1.85)] patients
Kooiman, 2014, The Netherlands <sup>83</sup>	724 AF patients without CKD or non-dialysis-dependent CKD on OAC attending the Leiden clinic between 1997 and 2005 Follow-up: 31 December 2010 Median follow-up 2.1 years for stroke/TIA and 2.3 years for major bleeding events Mean (SD) age 75 (10); 43.5% women	Abbreviated MDRD formula No CKD (eGFR >60 mL/min): $n = 300$ Moderate CKD (30–60 mL/min): $n = 294$ Severe CKD (eGFR <30 mL/min) = 130	All OACs	45/724 (6.2%) (1.67/100 patient-years) stroke/TIA ↑ Stroke/TIA risk in patients with severe CKD vs. those without CKD [HR (95% CI) 2.75 (1.25–6.05)] vs. those with moderate CKD [HR (95% CI) 3.93 (1.71–9.00)] Similar stroke/TIA risk for patients with moderate CKD vs. without CKD (data not reported)	ISTH criteria for major bleeding 113/724 (15.6%) (4.8/100 patient-years) Non-significant ↑ in major bleeding risk with severe CKD vs. no CKD [HR (95% CI) 1.66 (0.97–2.86)] and those with moderate CKD [HR (95% CI) 1.86 (1.08–3.21)] Similar risk of major bleeding for patients with moderate CKD vs. no CKD (data not reported)
Friberg, 2014, Sweden <sup>84</sup>	Retrospective analysis of Swedish AF national registry 307 351 patients with hospital diagnosis of AF between 1 July 2005 and 31 December 2010 13 435 (4.4%) with previous diagnosis of renal failure	ICD-10 codes (N17-19) or local codes for dialysis or renal transplantation Mean (SD) age; % women Renal failure: 78.4 (10.3); 4802 (35.7%) No renal failure: 74.8 (12.5); 123 333 (45.6%)	Warfarin at baseline Renal failure: 3766 (28.0%) No renal failure: 10 794 (39.9%)	↑ Annual rate of ischaemic stroke [3.9 vs. 2.9%; HR (95% CI) 1.25 (1.16–1.34)] and TE [8.2 vs. 5.2%; HR (95% CI) 1.42 (1.35–1.49)] with renal failure; however, no significant difference after full adjustment for confounders [adjusted HR (95% CI) 1.02 (0.95–1.10) and 1.12 (1.07–1.18) for ischaemic stroke and TE, respectively] Irrespective of renal function, patients on warfarin at baseline had ↓ stroke and TE than those not on warfarin at baseline [HR 0.69 vs. 0.70 in patients with and without renal failure; $P$ -value for interaction $P = 0.865$ ]	↑ Annual rate of any bleeding [9.8 vs. 4.1%; HR (95% CI) 2.24 (2.14–2.35)] and ICH [0.8 vs. 0.5%; HR (95% CI) 1.50 (1.28–1.74)] with renal failure Renal failure-independent risk factor for any bleeding [adjusted HR (95% CI) 1.56 (1.48–1.63)] and ICH [adjusted HR 1.27 (1.09–1.49)]

Continued

Table 6 Continued

Author, year, country	Study population	Definition of renal impairment	ATT therapy	Thromboembolic events	Bleeding events
Chao, 2014, Taiwan <sup>85</sup>	Retrospective analysis of Taiwan's National Health Insurance Research Database between 1 January 1996 and 31 December 2011 10 999 AF patients with ESRD undergoing renal replacement therapy, not on OAC or APT Mean (SD) age 71.0 (11.1) years; 5913 (53.8%) women	ESRD defined by ICD-9-CM codes	None	Ischaemic stroke 1217 pts. (11.7%); incidence rate of 6.9 per 100 patient-years	† 9.7% severe bleeding (bleeding not defined)
Roldán, 2013, Spain <sup>86</sup>	978 consecutive stable anticoagulated (INR 2.0–3.0 within previous 6 months) AF patients from outpatient clinic Median (IQR) age 76 (70–81); 482 (49.3%) women Median (IQR) follow-up: 875 (706–1059) days	MDRD Renal impairment: eGFR < 60 mL/min/1.73 m <sup>2</sup>	OAC	CV events (stroke, TIA, peripheral embolism, ACS, acute HF, and cardiac death) 113 patients (4.82%/year) adverse CV events; 39 (1.66%/year) strokes eGFR (categorical variable per 30 mL/min/1.73 m <sup>2</sup> decrease) was significantly associated with thrombotic/vascular events [unadjusted HR (95% CI) 1.42 (1.11–1.83); P = 0.006] Adjusted for 'high-risk' (CHA <sub>2</sub> DS <sub>2</sub> -VAsc score ≥ 2) eGFR (per 30 mL/min/1.73 m <sup>2</sup> decrease) was significantly associated with thrombotic/vascular events [adjusted HR (95% CI) 1.37; 1.07–1.76; P = 0.012]	ISTH criteria for major bleeding 81 patients (3.46%/year) haemorrhagic events 16 ICH (0.68%/year) eGFR (categorical variable per 30 mL/min/1.73m <sup>2</sup> decrease) ↑ risk of bleeding (HR 1.44; 1.08–1.94; P = 0.015) Adjusted for 'high-risk' (HAS-BLED ≥ 3) eGFR (per 30 mL/min/1.73 m <sup>2</sup> decrease) was significantly ↑ risk of bleeding [adjusted HR (95% CI) 1.34 (1.00–1.80); P = 0.046]
Banerjee, 2013, France <sup>87</sup>	Loire Valley cohort 5912 patients with first recorded AF diagnosis in hospital between 1 January 2000 and December 2010 with baseline serum creatinine data Mean follow-up: 2.45 (3.56) years	History of renal failure or baseline serum creatinine level >133 μmol/L (men) or >115 μmol/L (women) eGFR (mL/min/1.73m <sup>2</sup> ) three groups: ≥ 60 (n = 4375) 30–59 (n = 1196) < 30 (n = 341)		TE (ischaemic stroke, TIA, and peripheral artery embolism) No. TE events and rate (95% CI) at 1 year eGFR ≥ 60: 64; 3.4 (2.4–4.8) eGFR 30–59: 92; 5.7 (4.2–7.8) eGFR < 30: 15; 7.7 (4.3–13.6) Normal: 119; 4.4 (3.2–5.9) As a categorical variable only, eGFR was an independent predictor of TE after adjustment for age, sex, and CHADS <sub>2</sub> risk factors but not for baseline characteristics	†
Apostolakis, 2013, multicentre <sup>88</sup>	AMADEUS cohort 4576 AF patients. receiving OAC Mean (SD) age 70 (9) years; 1526 (33.4%) women Mean (SD) follow-up: 325 (164) days	Baseline serum creatinine available in 4554 (99.5%) Three most widely used equations to calculate renal function CrCl (Cockcroft–Gault formula), MDRD and CKD-EPI Based on CrCl: 1470 (32.35) < 60 mL/min 68 (1.5%) < 30 mL/min	Warfarin or idraparinux	Composite of all stroke/non-CNS SE 45 strokes/non-CNS SE (1.1 events per 100 patient-years) Only data for CrCl and MDRD reported here (number of events (n/100 patient-years)) CrCl ≥ 90: 6 (0.6) 60–89: 13 (0.8) 30–59: 26 (2.2) < 30: 0 MDRD ≥ 90: 2 (0.4) 60–89: 17 (0.8) 30–59: 25 (1.9) < 30: 1 (1.9) Adjustment for demographic characteristics and co-morbidities, patients with CrCl < 60 mL/min had double the risk of risk/SE compared with those with CrCl ≥ 60 mL/min [adjusted HR (95% CI) 2.27 (1.14–4.52)]	ISTH criteria for major bleeding 103 major bleeds (2.5 events per 100 patient-years) CrCl ≥ 90: 15 (1.3) 60–89: 38 (2.4) 30–59: 48 (3.8) < 30: 2 (3.2) MDRD ≥ 90: 7 (1.6) 60–89: 53 (2.4) 30–59: 42 (3.2) < 30: 1 (1.9) Patients with CrCl < 60 mL/min had ↑ risk of major bleeding compared with patients with CrCl ≥ 60 mL/min [adjusted HR (95% CI) 1.58 (1.05–2.39); P = 0.027]

Olesen, 2012, Denmark <sup>85</sup>	Retrospective analysis of Danish national registries 132 372 patients with hospital discharge diagnosis of AF between 1997 and 2008	ICD codes No renal disease at baseline: 127 884 (96.6%) Mean (SD) age 73.2 (12.9); 46.9% women Non-end-stage CKD: 3587 (2.7%) Mean (SD) age 76.5 (11.0); 41.0% women end-stage CKD (dialysis or previous kidney transplant): 901 (0.7%) Mean (SD) age 66.8 (11.7); 33.6% women	OAC ± ASA, ASA, or none	No. of stroke/TE events; event rate per 100 patient-years (95% CI) No renal disease: 16 648; 3.61 (3.55–3.66) Non-end-stage CKD: 842; 6.44 (6.02–6.89) End-stage CKD: 164; 5.61 (4.82–6.54) Compared with patients with no renal disease, non-end-stage CKD patients [HR (95% CI) 1.49 (1.38–1.59; $P < 0.001$ )] and those on renal replacement [HR (95% CI) 1.83 (1.57–2.14; $P < 0.001$ )] had ↑ risk of stroke/TE Warfarin ↓ stroke/TE risk in both groups [adjusted HR (95% CI)] No renal disease: ASA: 0.59 (0.56–0.61) OAC: 1.10 (1.06–1.14) OAC + ASA: 0.69 (0.64–0.74) Non-end-stage CKD: ASA: 0.84 (0.69–1.01) OAC: 1.25 (1.07–1.47) OAC + ASA: 0.76 (0.56–1.03) Renal replacement: ASA: 0.44 (0.26–0.74) OAC: 0.88 (0.59–1.32) OAC + ASA: 0.82 (0.37–1.80)	No. of major bleeding events; event rate per 100 patient-years (95% CI) No renal disease: 16 195; 3.54 (3.48–3.59) Non-end-stage CKD: 1097; 8.77 (8.26–9.30) Renal replacement: 243 8.89 (7.84–10.08) Adjusted HR (95% CI) No renal disease: ASA: 1.28 (1.23–1.33) OAC: 1.21 (1.16–1.26) OAC + ASA: 2.18 (2.07–2.30) Non-end-stage CKD: ASA: 1.36 (1.17–1.59) OAC: 1.12 (0.96–1.30) OAC + ASA: 1.63 (1.32–2.02) Renal replacement: ASA: 1.27 (0.91–1.77) OAC: 1.63 (1.18–2.26) OAC + ASA: 1.71 (0.98–2.99)
Go, 2009, USA <sup>90</sup>	ATRIA cohort 13 535 AF patients diagnosed between 1 July 1996 and 31 December 1997 Mean age of ATRIA cohort 71.6 years; 42.8% women Follow-up until 30 September 2003	MDRD Baseline serum creatinine not available in 2627 (19.4%) patients eGFR ≥ 60 mL/min/1.73 m <sup>2</sup> : $n = 7690$ 45–59 mL/min/1.73 m <sup>2</sup> : $n = 2499$ <45 mL/min/1.73 m <sup>2</sup> : $n = 1338$	None 33 165 patient-years off-OAC among 10 908 AF patients	676 TE events (637 ischaemic strokes) during periods off-warfarin eGFR ≥ 60 mL/min/1.73 m <sup>2</sup> : 344 events 45–59 mL/min/1.73 m <sup>2</sup> : 168 events <45 mL/min/1.73 m <sup>2</sup> : 149 events 15 events in patients with unknown kidney function Crude rates of TE off-warfarin by eGFR eGFR ≥ 60: 1.63 45–59 : 2.76 <45: 4.22 Rate of TE off-warfarin ↑ significantly with lower eGFR Adjusted (for age, sex, ethnicity, education, income, previous stroke, HF, DM, hypertension, and CHD) HR (95% CI) for TE compared with eGFR ≥ 60 eGFR 45–59: 1.16 (0.95–1.40) eGFR <45: 1.39 (1.13–1.71) Graded increased independent risk of TE with eGFR <45 mL/min/1.73 m <sup>2</sup>	†

AMADEUS, Atrial fibrillation trial of Monitored, Adjusted Dose vitamin K antagonist, comparing Efficacy and safety with Unadjusted SanOrg 34006/Idraparinux study; ACS, acute coronary syndrome; AF, atrial fibrillation; ASA, aspirin; ATRIA, Anticoagulation and Risk factors in Atrial fibrillation; ATT, antithrombotic therapy; CI, confidence interval; CKD, chronic kidney disease; CKD-EPI, chronic kidney disease epidemiology collaboration equation; CNS, central nervous system; CrCl, creatinine clearance; CV, cardiovascular; eGFR, estimated glomerular filtration rate; CKD, chronic kidney disease; ESRD, end-stage renal disease; HF, heart failure; HR, hazard ratio; ICD, International Classification of Disease; ICH, intracranial haemorrhage; IQR, interquartile range; ISTH, International Society of Thrombosis and Haemostasis; MDRD, Modification of Diet in Renal Diet; min, minute; mL, millilitres; NOAC, non-vitamin K antagonist oral anticoagulant; OAC, oral anticoagulation; SD, standard deviation; TE, thromboembolism; TIA, transient ischaemic attack; vs., versus.

†, not reported; \*, included in meta-analysis<sup>81</sup>; ↑, increase; ↓, decrease.

**Table 7** Annual rates of stroke/systemic embolism in patients with normal and impaired renal function enrolled in NOAC phase III trials

Trial	Stroke/SE in patients with eGFR $\geq 50$ mL/min (%/year)		HR (95% CI)	Stroke/SE in patients with eGFR 30–49 mL/min (%/year)		HR (95% CI)	P-value for interaction
	Intervention	Control		Intervention	Control		
RE-LY <sup>a1</sup>	$\geq 80$ mL/min	Warfarin	0.84	Dabigatran 110 mg	Warfarin	0.85	0.91
	Dabigatran 110 mg	1.05	(0.54–1.32)	2.32	2.70	(0.59–1.24)	
	Dabigatran 150 mg	Warfarin	0.67	Dabigatran 150 mg	Warfarin	0.56	0.75
	0.71	1.05	(0.42–1.09)	1.53	2.70	(0.37–0.85)	
	50–79 mL/min	Warfarin	0.93				
	Dabigatran 110 mg	1.83	(0.70–1.23)				
1.69	Warfarin	0.68					
Dabigatran 150 mg	1.83	(0.50–0.92)					
1.25							
AVERROES <sup>c2</sup>	$\geq 60$ mL/min	Aspirin 81–324	0.57	$< 60$ mL/min	Aspirin 81–324	0.32	0.10
	Apixaban 5 mg <sup>b</sup>	2.8	(0.37–0.87)	Apixaban 2.5–5 mg <sup>b</sup>	5.6	(0.18–0.55)	
ARISTOTLE <sup>d33</sup>	1.7			1.8			0.71
	$> 80$ mL/min	Warfarin	0.88	Apixaban 2.5–5 mg <sup>b</sup>	Warfarin	0.79	
	Apixaban 5 mg <sup>b</sup>	1.12	(0.64–1.22)	2.11	2.67	(0.55–1.14)	
	0.99						
$> 50$ –80 mL/min	Warfarin	0.74					
Apixaban 5 mg <sup>b</sup>	1.69	(0.56–0.97)					
1.24							
ROCKET-AF <sup>e94</sup>	Rivaroxaban 20 mg	Warfarin	0.78	Rivaroxaban 15 mg	Warfarin	0.84	0.76
	1.57	2.00	(0.63–0.98)	2.32	2.77	(0.57–1.23)	

ARISTOTLE, Apixaban for Reduction In STroke and Other ThromboemboLic Events in atrial fibrillation; AVERROES, Apixaban VErSUS acetylsalicylic acid to Reduce the Risk Of Embolic Stroke; RE-LY, Randomized Evaluation of Long-term anticoagulation therapy; ROCKET-AF, Rivaroxaban Once daily oral direct factor Xa inhibition Compared with vitamin K antagonism Trial in Atrial Fibrillation.

<sup>a</sup>RE-LY compared creatinine clearance  $\geq 80$  vs. 50–79 vs.  $< 50$  mL/min.

<sup>b</sup>Serum creatinine  $> 133$  mmol/L plus aged  $\geq 80$  years or body weight  $\leq 60$  kg.

<sup>c</sup>AVERROES compared eGF  $\geq 60$  vs.  $< 60$  mL/min.

<sup>d</sup>ARISTOTLE compared eGFR  $\leq 50$  vs.  $> 50$ –80 vs.  $> 80$  mL/min.

<sup>e</sup>On treatment analyses reported.

**Table 8 Annual rates of major bleeding in patients with normal and impaired renal function enrolled in NOAC phase III trials**

Trial	Major bleeding in patients with eGFR $\geq 50$ mL/min (%/year)		HR (95% CI)	Major bleeding in patients with eGFR 30–49 mL/min (%/year)		HR (95% CI)	P-value for interaction
	Intervention	Control		Intervention	Control		
RE-LY <sup>a90</sup>	$\geq 80$ mL/min	Warfarin	0.61 (0.44–0.84)	Dabigatran 110 mg	Warfarin	0.99 (0.77–1.28)	0.06
	Dabigatran 110 mg	2.43		5.45	5.49		
	Dabigatran 150 mg	Warfarin	0.84 (0.62–1.13)	Dabigatran 150 mg	Warfarin	1.01 (0.79–1.30)	
	2.04	2.43		5.50	5.49		
	50–79 mL/min	Warfarin	0.76 (0.62–0.94)	Dabigatran 110 mg	Warfarin	0.91 (0.75–1.11)	
	Dabigatran 110 mg	3.70		2.84	3.70		
Dabigatran 150 mg	3.70	3.35		3.70			
AVERROES <sup>c91</sup>	$\geq 60$ mL/min	Aspirin 81–324	1.1 (0.56–2.0)	< 60 mL/min	Aspirin 81–324	1.2 (0.65–2.1)	0.82
	Apixaban 5 mg <sup>b</sup>	0.8		Apixaban 2.5–5 mg <sup>b</sup>	2.2		
ARISTOTLE <sup>d92</sup>	> 80 mL/min	Warfarin	0.80 (0.61–1.04)	Apixaban 2.5–5 mg <sup>b</sup>	Warfarin	0.79 (0.55–1.14)	0.03
	Apixaban 5 mg <sup>b</sup>	1.84		3.221	6.44		
	> 50–80 mL/min	Warfarin	0.77 (0.62–0.94)	Apixaban 2.5–5 mg <sup>b</sup>	Warfarin	0.79 (0.55–1.14)	
	Apixaban 5 mg <sup>b</sup>	3.21		3.221	6.44		
ROCKET-AF <sup>e93</sup>	Rivaroxaban 20 mg	Warfarin	1.07 (0.91–1.26)	Rivaroxaban 15 mg	Warfarin	0.95 (0.72–1.26)	0.48
	3.39	3.17		4.49	4.70		

ARISTOTLE, Apixaban for Reduction In Stroke and Other Thromboembolic Events in atrial fibrillation; AVERROES, Apixaban Versus acetylsalicylic acid to Reduce the Risk Of Embolic Stroke; RE-LY, Randomized Evaluation of Long-term anticoagulation therapy; ROCKET-AF, Rivaroxaban Once daily oral direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation.

<sup>a</sup>RE-LY compared creatinine clearance  $\geq 80$  vs. 50–79 vs. < 50 mL/min.

<sup>b</sup>Serum creatinine > 133 mmol/L plus aged  $\geq 80$  years or body weight  $\leq 60$  kg.

<sup>c</sup>AVERROES compared eGFR  $\geq 60$  vs. < 60.

<sup>d</sup>ARISTOTLE compared eGFR  $\leq 50$  vs. > 50–80 vs. > 80 mL/min.

<sup>e</sup>On treatment analyses reported.

outweigh the reduction in stroke by warfarin.<sup>82</sup> Nonetheless, the Swedish AF cohort study suggests that the quality of anticoagulation control, as reflected by the average TTR matters more, since high TTR is associated with a lower risk of thromboembolism and bleeding.<sup>84</sup> All the non-VKA oral anticoagulants (NOACs) have a degree of renal excretion, and in their respective trials, those with severe renal failure were excluded. Thus, guidelines recommend that the NOACs are best used as they were studied in their respective trials, and should not be used where severe renal impairment (eGFR <25–30 mL/min) is evident, while dose reduction is needed if eGFR is between 30 and 49 mL (min).<sup>80</sup>

### Association with other co-morbidities (hypertension, chronic obstructive pulmonary disease, etc.)

Chronic kidney disease often does not occur in isolation, and is often present in AF patients given their increased age, associated co-morbidities, and concomitant drug therapies. Normal or mild renal function at baseline does not preclude some AF patients developing severe renal impairment at follow-up. Therefore, appropriate monitoring of renal function is indicated in patients with co-morbidities, as well as in frail patients. Indeed, ~20% of AF patients show a significant reduction in eGFR over a 2-year follow-up period.<sup>86</sup> Given the close relationship between AF and other arrhythmias with heart failure, a presentation with decompensated heart failure and the concomitant use of diuretics, ACE inhibitors, etc. may significantly compromise renal function, especially in patients with reduced renal reserve.

Various additional co-morbidities present among patients with AF and CKD may predispose to cardiac arrhythmias, especially AF. Hypertension is closely related to CKD, in a bidirectional relationship. Poorly controlled hypertension increases adverse cardiovascular events in patients with AF.<sup>106</sup> Treatment of hypertension with an ACE inhibitor or angiotensin receptor blocker may reduce new onset AF and cardiovascular events, particularly among the elderly.<sup>107</sup> The presence of hypertensive LV hypertrophy increases the risk of incident AF, and associated cardiovascular events.<sup>108,109</sup>

Respiratory conditions such as obstructive sleep apnoea and chronic obstructive pulmonary disease (especially if both are present) have been associated with incident arrhythmias.<sup>110</sup> Sleep apnoea may contribute to cardiovascular events in this population;<sup>111,112</sup> indeed, sleep apnoea does improve the predictive value of the CHADS<sub>2</sub> score for stroke risk.<sup>113</sup> Severity of sleep apnoea may influence the degree of responsiveness to antiarrhythmic drugs.<sup>114</sup>

Excessive alcohol consumption predisposes to AF,<sup>115,116</sup> and importantly, increases the risk of stroke and death among AF patients,<sup>117</sup> as does high body mass index, as an index of obesity.<sup>118</sup> Conversely, lifestyle changes, including weight reduction, have a positive impact on AF progression. In a recent randomized trial, weight reduction with intensive risk factor management resulted in a reduction in AF symptom burden and severity as well as in beneficial cardiac remodelling.<sup>119</sup>

### Contrast-induced acute kidney injury

This section is described in Supplementary material online.

## Implications of arrhythmias in the management of a patient with chronic kidney disease

### Ventricular tachyarrhythmias and sudden death in advanced chronic kidney disease and in patients treated with haemodialysis

Sudden cardiac death is the most common cause of death in dialysis patients, even in the paediatric population,<sup>120</sup> accounting for over 50% of all cardiac deaths and 25% of all deaths.<sup>29,121–125</sup> The risk of SCD is also increased in patients with non-dialysis-dependent CKD, with the risk of SCD increasing linearly with declining renal function.<sup>126–129</sup> The risk for SCD has been reported as being 17% higher for every 10 mL/min/1.73 m<sup>2</sup> decrease in eGFR.<sup>126</sup> The prognosis of cardiac arrests is worse in both dialysis patients and patients with stages of CKD corresponding to moderate-to-severe impairment of renal function.<sup>29,130,131</sup>

The mechanisms that underlie SCD in renal patients are complex and many factors, both general and specific to kidney failure, have been associated with the increased risk for SCD.<sup>131,132</sup> Ischaemic heart disease is present in 80% of patients with SCD in the general population and is highly prevalent in patients with CKD.<sup>32,133</sup> In patients starting dialysis, the prevalence of ischaemic heart disease is estimated at 40–60%<sup>29,134</sup> and its presence is associated with an increased risk of SCD.<sup>135</sup>

Left ventricular hypertrophy and its associated decreased myocardial capillary density and disturbances in intraventricular conduction, as well as LV diastolic and systolic failure/dysfunction, predispose to ventricular arrhythmias and SCD.<sup>31,136</sup> The prevalence of all of these features increases with a decreasing GFR and all of them are very common in dialysis patients.<sup>137–139</sup> Vascular disease in CKD is not only characterized by intimal atheroma but also by arteriosclerosis, a disease of the medial arterial layer associated with increased collagen content and calcification.<sup>31,32</sup> Increased arterial stiffness is associated with LV hypertrophy, myocardial fibrosis and LV dysfunction, as well as increased mortality.<sup>31,32</sup> Coronary artery calcification is associated with an increased spatial QRS-T angle, an important marker for SCD in various patient groups.<sup>140,141</sup> Sympathetic overactivity is highly prevalent in dialysis patients and starts early in the course of CKD, probably driven by kidneys themselves as it is reduced by nephrectomy.<sup>142,143</sup> In dialysis patients, plasma norepinephrine is independently associated with survival and cardiovascular events.<sup>144</sup>

Cardiac arrhythmias and SCD are more common on Mondays and Tuesdays after haemodialysis-free weekends, and during the 12 h after initiation of a haemodialysis session.<sup>145–148</sup> These findings suggest that major shifts in blood pressure, electrolytes, and fluid may induce triggers that result in arrhythmias.<sup>131,149</sup> The use of haemodialysis catheters, rather than an arteriovenous fistula, is also associated with an increased risk of SCD.<sup>149,150</sup> The risk of SCD in dialysis patients falls after successful transplantation.<sup>29</sup>

Most of the evidence available regarding approaches to reducing the risk of SCD in patients with CKD comes from subanalyses of population studies and clinical trials.<sup>131</sup> Beta-blockers reduce the risk of SCD in a number of high-risk populations.<sup>151–153</sup>

Randomized controlled trials providing this evidence have generally excluded individuals with CKD.<sup>154,155</sup> In dialysis patients, the use of beta-blockers may be limited by hypotensive episodes associated with fluid removal. A *post hoc* analysis suggests that the use of beta-blockers in patients with CKD is associated with a reduction in SCD risk.<sup>156</sup> Statin therapy is generally safe and is associated with significant reductions in cardiovascular mortality in patients with CKD receiving dialysis.<sup>157–159</sup>

Limited data exist on the reduction of SCD as a specific outcome. Dysregulation of the renin–angiotensin–aldosterone system is a fundamental abnormality in CKD with studies, demonstrating that elevated aldosterone concentrations are an independent risk factor for SCD in patients with CKD.<sup>160</sup> Whether ACE inhibitors and ARBs reduce SCD in patients with CKD is not clear.<sup>132</sup> However, use of an ACE inhibitor and/or ARB are associated with a significant reduction in the risk of SCD in dialysis patients with a positive correlation between drug dose and survival.<sup>161</sup> Mineralocorticoid receptor blockers are also known to reduce SCD by ~30% in clinical trials enrolling patients with heart failure,<sup>162</sup> and these benefits extend to the CKD subgroup. Nonetheless, use of these agents may be limited in patients with CKD, especially those on dialysis because of the associated potential for hyperkalaemia and hypotension.

Recently, several dialysis-related factors have been identified, which are associated with an increased risk for SCD, including increased fluid removal and exposure to low potassium dialysate, thereby providing potentially useful methods for altering dialysis treatment.<sup>163</sup> Various modifications have been prospectively investigated including increased frequency and dose of dialysis. Encouraging effects on surrogate endpoints (such as LV mass) have been reported with long-hours nocturnal haemodialysis.<sup>164,165</sup> No beneficial effects have been reported with regard to reducing (cardiovascular) mortality thus far.<sup>149</sup>

## **Atrial fibrillation and supraventricular tachyarrhythmias in advanced chronic kidney disease and in the chronic kidney disease patient treated with haemodialysis: haemodynamic effects and acute and long-term treatments**

Despite the existence of well-established, evidence-based approaches to symptomatic control (rhythm and rate) of AF,<sup>80,166</sup> most studies have excluded patients with functionally significant CKD.<sup>167</sup> There are multiple clinically relevant and important differences in this group of complex patients, suggesting that accepted treatment strategies may not be as effective or indeed may cause significant adverse effects and harm.<sup>167</sup>

Perhaps, the most important relates to the occurrence of intradialytic hypotension in ~20–30% of dialysis sessions, as the direct result of an inadequate cardiovascular response to the reduction in blood volume that occurs when a large volume of water is removed during a short period of time.<sup>168–173</sup> This needs urgent treatment by stopping ultrafiltration, placing the patient in the Trendelenburg position and saline administration. Such episodes often result in volume overload leading to LV remodelling, diastolic and systolic dysfunction, and arrhythmogenic myocardial fibrosis.<sup>170</sup> Indeed,

intradialytic hypotension is associated with a significant increase in cardiovascular morbidity and mortality.<sup>168–171</sup>

As in the general population, for patients with CKD presenting with newly diagnosed AF, the short-term treatment goal should be control of their symptoms with rate or rhythm control therapies.<sup>174,175</sup> Except for the need of emergency cardioversion to restore sinus rhythm in patients with haemodynamic instability, the initial therapeutic approach should include assessment for the underlying causes of AF and ventricular rate control to improve haemodynamic status and relieve symptoms.<sup>80,168,174–176</sup>

Recent studies in the AF population have suggested that lenient control (<110 b.p.m.) of resting heart rate was associated with better outcomes than strict control (80 b.p.m.),<sup>177</sup> and that rhythm control through DC cardioversion does not improve outcomes compared with rate control using beta-blockers and digoxin.<sup>178</sup> Whether these results are applicable to patients with CKD, especially those on dialysis, is uncertain. The differences in cardiovascular function and structure, especially in blood vessel compliance, as well as the compensatory haemodynamic changes required during routine fluid removal in a haemodialysis session might well modify the relationships between rhythm control, rate control, and outcomes.<sup>179</sup> An estimated 20% of ventricular filling is a consequence of atrial contraction and its importance may well be exaggerated during episodes of cardiovascular stress during a haemodialysis session.<sup>179</sup>

In CKD, there are limited data on safety for any of the agents recommended for rate and rhythm control (amiodarone, dronedarone, propafenone, and flecainide), not to mention the risks associated with anticoagulation.<sup>180</sup> Therefore, catheter-based ablation is increasingly used for rhythm control also in this complex clinical context. In patients with CKD with an eGFR of  $\geq 30$  mL/min/1.73 m<sup>2</sup>, maintenance of sinus rhythm following AF ablation (achieved in ~74% of patients at 1 year) was associated with a significant improvement in renal function.<sup>181</sup> Even in the specific setting of CKD patients, persistent AF and underlying atrial fibrosis resulted the main determining factor of success.<sup>181</sup> In general, catheter ablation is associated with reduced rates of symptomatic AF recurrence compared with drug treatment for rhythm and rate control.<sup>182,183</sup> In patients under haemodialysis radiofrequency, catheter ablation is increasingly performed for rhythm control of AF, since the use of antiarrhythmic agents is largely restricted in this context. Small studies suggest that the technique might not be as effective as in the general population.<sup>184,185</sup> In a single-centre study with a 5-year follow-up, multiple ablation procedures for AF achieved an efficacy of ~80% in terms of sinus rhythm maintenance, similar to the efficacy of non-haemodialysis patients, whereas the efficacy of a single procedure was scarce.<sup>186</sup> Other reports confirm the high recurrence rate of AF in haemodialysis patients and the need for repeated procedures.<sup>187</sup> In CKD patients treated with AF ablation, the risk of procedure-related vascular complications is increased in comparison with patients with normal kidney function.<sup>71</sup> His bundle ablation is another option, targeted at rate control, but requires a pacemaker implant.

## **Antiarrhythmics, beta-blockers, antithrombotics, and dialysis**

This section is presented in Supplementary material online.

## Implications of arrhythmias in the perioperative management of a patient with chronic kidney disease

Patients with CKD not only have an increased risk of CVD, but also a worse associated prognosis.<sup>12</sup> Cardiac mortality is 10- to 20-fold greater in dialysed patients than in matched controls.<sup>188</sup> Chronic kidney disease patients frequently have structural cardiac disease and abnormal ventricular function, and are therefore at higher risk of developing ventricular arrhythmias in the perioperative period.<sup>189</sup> Arrhythmias are already present in 32% of dialysis patients.<sup>190</sup>

Preoperative medical optimization prior to elective surgery includes appropriate dialysis prescription, correction of anaemia and electrolyte imbalance (with special focus on hyperkalaemia), tailoring blood pressure, and heart failure treatment and strategies to reduce perioperative bleeding. Assessment of the cardiac risk is mandatory preoperatively in order to avoid ischaemic and arrhythmic complications.<sup>191</sup> The Revised Cardiac Risk Index is a simple and valuable tool in this regard; a score of  $\geq 3$  defines a high-risk patient.<sup>192</sup> Furthermore, renal function may deteriorate postoperatively and strategies to protect against this may include adequate hydration, avoidance of nephrotoxins, and specific therapies to prevent contrast-induced nephrotoxicity. Patients with type 2 diabetes are often treated with the biguanide metformin, which is excreted by the kidney. Metformin needs to be withheld for 48 h from the time of an angiographic study if intravenous iodinated contrast media are to be given, in order to prevent high serum metformin concentrations, that in case of contrast-induced nephropathy could lead to lactic acidosis.

Beta-blockers should be continued during the perioperative period in patients receiving this therapy as outlined in contemporary guidelines.<sup>189</sup> Initiation of beta-blockers for high-risk non-cardiac surgery may also be considered. However, the effect of beta-blockers in this setting is still debated.

Patients with CKD may present unique challenges in the perioperative management of arrhythmias. Generally, the above mentioned principles apply in the prevention of supraventricular and ventricular arrhythmias. Patients should be appropriately monitored. Particular attention should be given to the daily assessment of the corrected QT interval and heart rate. Patients with dysrhythmias should be approached in the same manner as the general population, but the choice of antiarrhythmic agents (including beta-blockers) and pacing devices, including implantable defibrillators, has to consider some specific recommendations, dictated by the potentially less favourable risk–benefit ratio of therapeutic options in this particular setting.<sup>193</sup>

A more detailed discussion about antiarrhythmic drug recommendations for CKD patients is presented elsewhere in this document. It is important to emphasize that even non-renally cleared drugs need to be used with caution in the CKD patient because of associated electrolyte abnormalities and the frequent co-existence of LV hypertrophy and heart failure.

Haemodynamically unstable ventricular arrhythmias should be treated by immediate cardioversion. Prevention of recurrent monomorphic ventricular arrhythmias in the perioperative phase may require therapy with amiodarone or the use of infusions of other antiarrhythmic drugs depending on their particular

pharmacokinetics and pharmacodynamic properties in renal patients. Catheter ablation strategies can be used in appropriate cases. Prevention of recurrent polymorphic ventricular tachycardia may require multiple strategies including cardiac pacing and/or isoprenaline infusion to prevent bradycardia, correction of hypokalaemia and hypomagnesaemia, and removal of QTc prolonging drugs.

## Implications of chronic kidney disease in the management of a patient with an implantable electrical device

### Impact of chronic kidney disease on indication to treatment and patients' outcomes in patients with cardiac implantable devices

#### Pacing for bradycardia

Pacemakers are implantable devices indicated mainly in patients with symptomatic, persistent, or intermittent bradycardia.<sup>194</sup> Although the current implantation technique has led to consider pacemaker implantation as similar to minor surgery, the implant and the subsequent follow-up are not free of risks or complications, either at short or long term, such as haematoma, pneumothorax, infection, or lead-related problems.<sup>194</sup>

Patient clinical status and co-morbidities increase the risk of complications.<sup>195</sup> There are limited data in the literature on the implications of permanent pacing on patients' outcome and pacemaker complications in patients with CKD. In a retrospective study of patients with CKD on haemodialysis, patients with an implanted pacemaker had greater long-term mortality, but propensity score analysis revealed that the presence of a pacemaker was not an independent predictor of mortality in this setting.<sup>196</sup>

In patients with pacemakers, capture threshold is affected by many factors, including potassium level, and loss of capture may occur in cases of severe hyperkalaemia, with the atrial myocardium usually being more sensitive than the ventricular myocardium to acute rise in potassium levels.<sup>197,198</sup> In view of frequent fluctuations of potassium levels, patients with CKD could benefit, in terms of increased safety and extended device longevity, from devices with beat-to-beat automatic ventricular threshold adjustment on the basis of automatic capture verification,<sup>199</sup> but no specific data on CKD patients are available in the literature.

The practical issue of limitations in vascular access in the presence of a cardiac implantable electronic device (CIED) in a patient with or approaching ESRD should be considered. Arteriovenous access created ipsilateral to CIED placement should be avoided as much as possible, since they have a higher primary failure rate compared with the contralateral arm.<sup>200</sup> In case of pacemaker implant in a patient with previous arteriovenous fistula, the pacemaker should be implanted on the contralateral side.

In case of device replacement in patients with CKD, the possible interaction between anticoagulants, especially the NOACs, and renal function must be strictly monitored to minimize the risk of bleeding complications.<sup>79</sup>



### Cardiac resynchronization therapy for heart failure

About half of dialysis patients will develop heart failure either at presentation or during follow-up,<sup>201</sup> and CKD has a prevalence ranging up to 55% in patients with heart failure, with poor prognostic implications. In patients with ESRD, cardiac resynchronization therapy (CRT) is sometimes perceived as being at a potentially greater risk with fewer benefits. However, an analysis of the IMPROVE HF registry<sup>202</sup> showed that implants of CRT device did not decline in the subgroups of patients with more advanced stages of CKD, according to eGFR.

Patients with ESRD have not been studied in the major randomized trials on CRT since they were excluded from enrolment. *Table 9* summarizes studies evaluating CRT in heart failure patients with mild-to-moderate CKD and in heart failure patients with ESRD also treated with haemodialysis.<sup>203–211</sup> In general, these data from several studies and a meta-analysis suggest<sup>203–211</sup> that mild-to-moderate CKD is associated with benefits from CRT similar to those observed in heart failure patients without CKD, but with a higher risk of adverse outcomes.<sup>203,211</sup> More advanced CKD is an independent predictor of cardiac mortality and heart failure hospitalization.<sup>210</sup> Furthermore, although CRT can be safely performed in most patients with CKD, it has usually a limited impact on delaying or preventing deterioration of renal function, up to the stage requiring haemodialysis.<sup>207</sup> In patients with mild heart failure (NYHA Class I and II), enrolled in the REVERSE study, CRT in patients with CKD improved LV function and induced a reverse LV remodelling, although to a lesser extent than in those with normal kidney function.<sup>208</sup>

### Implantable cardioverter-defibrillator for sudden death

Patients with CKD are at a markedly increased risk of death from cardiovascular causes, including SCD. In patients with CKD, SCD accounts for over 50% of all cardiac deaths and 25% of all deaths, and its estimated annual rate is ~7%.<sup>29,121–124</sup>

The role of implantable cardioverter-defibrillators (ICDs) in this subgroup of patients is difficult to assess. First, randomized clinical trials of ICD therapy provide limited data regarding patients with CKD and ESRD because, in most trials, these patients were either excluded or the renal function was not reported. In addition, data on the ICD effect in CKD are somewhat divergent. *Table 10* summarizes the most relevant studies which have evaluated the role of ICD therapy in CKD patients.<sup>121,212–217</sup>

In general, it is expected that given the substantial co-morbidities in patients with CKD, the benefit of ICD therapy may be attenuated. Chronic kidney disease patients have an increased mortality due to other cardiac and non-cardiac causes; elevated defibrillation thresholds may render the myocardium refractory to ICD therapy and the higher complication rate may negate the benefit of ICD implantation in CKD patients. A recent study assessed the association between kidney function and ICD-related complications.<sup>218</sup> In a cohort of 3147 patients, implanted at a single centre from 1996 to 2012, comparisons were made between patients with normal, moderately, and severely impaired kidney function. Patients with eGFR < 30 mL/min/1.73 m<sup>2</sup> had a higher rate of haematoma, pneumothorax, and infection. In a retrospective analysis, CKD was associated with adverse prognosis after ICD implantation, but not after CRT with a

defibrillator (CRTD) implantation and GFR decreased in patients with ICD, but not in CRTD patients.<sup>219</sup>

There is still uncertainty about the benefit of the ICD for primary prevention of SCD in CKD patients.<sup>220,221</sup> A thorough assessment of individual risk/benefit of the therapy should guide decisions in this situation. The survival benefit observed in CKD patients who receive the ICD for secondary prevention of SCD favours use of ICD therapy in this population<sup>121,201</sup> (*Table 10*). In view of these data, withholding device therapy based only on the presence of CKD would be inappropriate in that specific setting. On the other hand, data indicate that primary prevention of SCD by an ICD does not convey a prognostic benefit in patients on haemodialysis, with a creatinine clearance of <35 mL/min<sup>126</sup> or BUN >26 mg/dL in conjunction with at least two other factors (age >70 years, NYHA >II, AF, and bundle branch block).<sup>222</sup> In another study based on a decision-analysis model for patients with CKD,<sup>223</sup> the benefit from primary prevention ICD implantation was strictly linked to patient's age, in combination with the stage of CKD. The result suggests careful consideration of ICD implantation for older patients with more advanced stages of CKD.

Recently, there has been a growing interest in subcutaneous ICD, a device with an electrode system that is placed entirely outside the thoracic cavity.<sup>224</sup> Interest was fuelled by the possibility of resolving problems related to access to the heart via the vascular system and problems linked to transvenous leads. According to early reports from the EFFORTLESS S-ICD Registry, CKD was present in 9% of the patients implanted with a subcutaneous ICD, but no specific data on patients' outcomes and device performance in this specific population are currently available.<sup>224</sup>

Another option that can be considered for protecting against the risk of SCD is the wearable cardioverter-defibrillator.<sup>225</sup> This device can be a valid solution in situations with a high, but transient increase in arrhythmic risk, such as the early phase after a large myocardial infarction with marked depression of LV function, or the acute phase of a myocarditis.

### Risk of infections and management

Cardiac implantable electronic devices are increasingly used in patients with CKD and ESRD,<sup>226</sup> with a reported prevalence of ~4% for pacemakers and 6% for ICDs.<sup>227,228</sup> In North America, the rate of utilization of ICDs dramatically increased after 2000.<sup>229</sup> Unfortunately, CIED infection rates increase faster than implantation rates.<sup>230,231</sup> Analysis of hospital discharge records including 4.2 million CIED implantations performed in the USA from 1993 to 2008 showed that 69 000 patients required treatment for CIED infection.<sup>232</sup> The average annual increase in CIED implantation was 4.7%, while the incidence rate of infection increased by 210% from 2660 cases in 1993 to 8230 cases in 2008. The annual rate of infection rose at a steady pace until 2004 when it jumped from 1.53% during that year to 2.41% in 2008 ( $P < 0.001$ ).<sup>232</sup> Renal failure was one of the most significant co-morbidities associated with infection, along with respiratory failure, heart failure, and diabetes.<sup>233</sup> Consistently, GFR <60 mL/min has been shown to be part of a six factor score predicting the risk of CIED infection.<sup>234</sup> A retrospective analysis of 1651 patients showed that scores ranged from 0 to 25 and identified three risk groups, i.e. low: score 0–7 with 1% infection,

**Table 9** Summary of studies evaluating the role of CRT therapy in heart failure patients with CKD

Author	Type of study	Number of patients	Follow-up duration	Definition of CKD	Main conclusion
Cleland et al. <sup>203</sup> (2005)	Randomized controlled trial	813 heart failure patients randomized to medical therapy alone or with CRT	29.4 months	GFR <60.3 mL/min/1.73 m <sup>2</sup> (median of the population)	If reduced GFR same benefit of CRT vs. medical therapy alone with regard to death from any cause or unplanned hospitalization for a major cardiovascular event
Shalabi et al. <sup>204</sup> (2008)	Single-centre retrospective cohort study	330 patients with severe heart failure treated with CRT	19.7 ± 9.0 months	Elevated serum creatinine	Worse survival free of death or heart failure hospitalization in the highest tertile of serum creatinine compared with all others. For each 0.1 mg/dL increase in creatinine level, there was an 11% increase in mortality
Van Bommel et al. <sup>205</sup> (2010)	Registry	716 heart failure patients treated with CRT	25 ± 19 months		Lower GFR at baseline was strongly predictive of death [HR of 1.18 per decrease of 10 mL/min/1.73 m <sup>2</sup> (95% CI 1.09–1.27, P < 0.001)]
Goldenberg et al. <sup>206</sup> (2010)	Post hoc analysis of patients enrolled in the MADIT CRT trial	1803 patients with mild heart failure randomized to CRTD or ICD treatment	12 months	Ratio of blood urea nitrogen to serum creatinine (an index of prerenal function)	An elevated ratio of blood urea nitrogen to serum creatinine experienced a significantly greater reduction in the risk of heart failure or death with CRTD therapy when compared with patients with a low ratio
Lin et al. <sup>207</sup> (2011)	Single-centre retrospective cohort study	CRT in 482 heart failure patients, of whom 71% had CKD	36.45 + 26.55 months	GFR ≤60 mL/min/1.73 m <sup>2</sup>	Survival was superior in patients with normal or mild renal dysfunction compared with patients with CKD
Mathew et al. <sup>208</sup> (2012)	Post hoc analysis of patients enrolled in the REVERSE trial	561 patients with mild heart failure randomized to CRT or control therapy	12 months	GFR <60 mL/min/1.73 m <sup>2</sup>	CRT improves LV function and reduces LV volumes to a lesser extent in patients with CKD than in those with normal kidney function
Friedman et al. <sup>209</sup> (2013)	Case–control study	15 dialysis-dependent heart failure patients and a control group of CRT patients	Up to 3 years	Dialysis	In dialysis patients, CRT implantation has no serious complications and certain patients have important improvement. Compared with matched controls, dialysis patients are at an increased risk for adverse events
Hosoda et al. <sup>210</sup> (2014)	Single-centre retrospective cohort study	CRT in 15 dialysis-dependent heart failure patients	30.3 ± 22.0 months	eGFR <50 mL/min	Patients with a e-GFR of <50 mL/min had significant higher all-cause mortality (log-rank P = 0.033) and higher cardiac mortality combined with HF hospitalization (log-rank P = 0.017) than those with eGFR ≥50 mL/min
Garg et al. <sup>211</sup> (2013)	Meta-analysis of 14 observational studies and 4 randomized trials 9419 patients	Heart failure patients treated with CRT	1–4.25 years	eGFR <45 or 60 mL/min/1.73 m <sup>2</sup> ; creatinine level >1.5 or 1.8 or 2 mg/dL; haemodialysis	Modest improvement in eGFR with CRT among CKD patients (mean difference 2.30 mL/min/1.73 m <sup>2</sup> ; 95% CI 0.33–4.27). Similarly, a significant improvement in LV ejection with CRT in CKD patients (mean difference 6.24%; 95% CI 3.46–9.07)

CKD, chronic kidney disease; CRT, cardiac resynchronization therapy; CRTD, cardiac resynchronization therapy plus defibrillation; eGFR, estimated glomerular filtration rate; HR, hazard ratio.

**Table 10** Summary of studies evaluating the role of ICD therapy in CKD patients

Author	Type of study	ICD indication	Number of patients	Follow-up duration	Definition of CKD	Main conclusion
Herzog <i>et al.</i> <sup>121</sup> (2005)	Registry	Secondary prevention	460 ICD group and 5582 no-ICD group	17.9 ± 15.5 months (ICD) 14.0 ± 14.9 months (no-ICD)	Haemodialysis patients	ICD implantation reduces the risk of death by 42%
Korantzopoulos <i>et al.</i> <sup>212</sup> (2009)	Meta-analysis of 11 observational studies	Primary and secondary prevention	735 CKD patients out of 3010	1–4.25 years	eGFR < 45 or 60 mL/mm/1.73 m <sup>2</sup> ; creatinine level > 1.5 or 1.8 or 2 mg/dL; haemodialysis	Mortality is 3.44-fold higher in CKD patients
Sakhuja <i>et al.</i> <sup>213</sup> (2009)	Meta-analysis of six retrospective cohort studies and one case–control study	Primary and secondary prevention	89 haemodialysis patients out of 2516	12–48 months	Haemodialysis; an eGRF value of 60 mL/mm/1.73 m <sup>2</sup>	Mortality is 2.67-fold higher in haemodialysis patients No difference in mortality between haemodialysis and CKD patients
Hage <i>et al.</i> <sup>214</sup> (2013)	Single-centre retrospective cohort study	Primary vs. secondary prevention	409 primary prevention (141 CKD) 287 secondary prevention (115 CKD)	50 ± 24 months	eGFR < 60 mL/mm/1.73 m <sup>2</sup>	In CKD, higher mortality risk for primary but not secondary prevention patients; Higher risk of appropriate therapy for primary but not secondary prevention patients
Pun <i>et al.</i> <sup>215</sup> (2014)	Meta-analysis of randomized control trials	Primary prevention	1040 CKD 1827 no-CKD	2.7 ± 1.5 years	eGFR < 60 mL/mm/1.73 m <sup>2</sup>	Survival benefit with ICD in patients with eGFR ≥ 60 mL/mm/1.73 m <sup>2</sup> only
Hess <i>et al.</i> <sup>216</sup> (2014)	Registry	Primary prevention	21 226 CKD 26 056 no-CKD	2.9 years [2.4–3.3]	eGFR ≤ 60 mL/mm/1.73 m <sup>2</sup>	Graded higher risk of death [2.08–4.8 HR] depending on the severity of renal failure
Makki <i>et al.</i> <sup>217</sup> (2014)	Meta-analysis of: observational retrospective studies Observational studies (retrospective prospective)	Primary and secondary prevention	Role of ICD in CKD patients: 17 160 CKD Effect of CKD in ICD recipients: 5233 (1843 CKD)	17–48 months 12–51 months	eGFR < 60 mL/mm/1.73 m <sup>2</sup> ; creatinine level > 1.5 or 1.8 or 2 mg/dL; haemodialysis	The ICD provides survival benefit in CKD patients at a high risk of SCD [HR = 0.65] CKD is associated with an increase in all-cause mortality in ICD recipients [HR = 2.86]

ICD, implantable cardiac defibrillator; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; HR, hazard ratio.

medium: score 8–14 with 3.4% infection, and high: score  $\geq 15$  with 11.1% infection.

Chronic kidney disease is one of the main risk factors for mortality (OR: 4.28; 95% CI 4.04–4.53) in CIED-infected patients.<sup>232,235,236</sup> The clinical presentation of CIED infection in haemodialysis patients differs from non-haemodialysis patients, being more frequently bloodstream and complicated by lead-related endocarditis; however, pocket infection is less frequently observed.<sup>236</sup> Uraemia is associated with a state of immune dysfunction characterized by immunodepression that contributes to the high prevalence of infections among these patients, as well as by immunoactivation resulting in inflammation.<sup>237</sup> A progressive increase in the risk of bleeding complications following CIED implantation as the degree of renal insufficiency worsens has been shown.<sup>238</sup> Impaired platelet function and coagulation abnormalities may also play a role in this excessive risk of bleeding. Moreover, a significant number of patients receive haemodialysis through central venous catheters, which are known to be associated with very high rates of catheter-related bacteraemia and subsequent risk of transvenous CIED infection.<sup>239</sup> To minimize the risk of infections, in candidates to implant a CIED, the type of device (single- or multichamber), the access and routes for leads implantation should be decided on an individual basis, taking into account the increased risk for infection and vascular complications associated with more complex implant (such as CRT). Antibiotic prophylaxis should always be prescribed at the time of CIED implant. In patients already implanted with a transvenous CIED, dialysis catheter should be avoided and contralateral access for arteriovenous fistula should be preferred.

The general principles of CIED infection treatment involve effective antibiotic treatment, complete removal of the generator and leads, and implantation of a new system on an 'as-needed' basis.<sup>240,241</sup> These principles apply to ESRD patients. Small series show that device removal in haemodialysis patients is not associated with a higher rate of complication when compared with non-haemodialysis patients. However, device removal is less frequently performed in haemodialysis patients (82 vs. 95% of the cases), probably reflecting the perception of increased risk and poor prognosis in this population.<sup>236</sup> In a recent study, 29.4% of 503 patients undergoing CIED removal from 2001 to 2011 had advanced renal failure.<sup>242</sup>

Based on the high rate of infectious complications in haemodialysis and ESRD patients, non-endovascular routes (i.e. epicardial or subcutaneous) for implantation of CIEDs should be considered.<sup>239,242</sup> The rationale behind this proposal is that epicardial or subcutaneous leads traverse the subcutaneous tissue and do not use the central venous system. In these cases, experienced operators may reduce the time of the procedure and procedure-related complications.

## Risk of syncope

This section is included in Supplementary material online.

## Pregnancy

This section is given in Supplementary material online.

## Life expectancy

This section is provided in Supplementary material online.

## Implications of an implantable electrical device on the management of a patient with chronic kidney disease

### Perioperative management for electromagnetic interferences

Chronic kidney disease does not represent a unique problem for the management of CIEDs in the perioperative setting. However, CKD patients frequently require surgical or endoscopic interventions and therapies that may expose the CIED to electromagnetic interference (EMI). Guidelines on the management of CIEDs in the perioperative setting<sup>243</sup> should be applied, focusing particularly on conditions where CIED function could be affected by the use of electrocautery.

The risk of such interference or damage to the pulse generator or pacemaker resetting is generally low in the modern era. Bipolar electrocautery is preferred to reduce the risk of device over-sensing and pacemaker inhibition or inappropriate ICD therapy. Bipolar electrocautery rarely causes significant EMI unless applied near to the CIED (<5 cm). Monopolar electrocautery is more likely to create EMI and pulses should be <5 s duration. Device reset is uncommon with electrocautery and electrocautery delivered below the umbilicus is considerably less likely to cause CIED interference. Device reset occurs infrequently with electrosurgery, and pacing threshold increase or undersensing due to damage to the electrode/myocardial tissue interface can occur. Therefore, all devices need to be checked after electrocautery. Patients with CKD and CIED are particularly prone to perioperative complications and thus require close perioperative monitoring. Reprogramming all pacemaker CIEDs to a non-sensing mode at the time of a procedure using electrocautery is not recommended. Likewise, routinely deactivating all ICD tachycardia therapies is also not recommended. Advice should be individualized, based on an individual patient profile, including evaluation of records from the CIED follow-up clinic.

The physician needs to know a series of device factors, such as type of device, type of leads (unipolar vs. bipolar), programming, battery longevity, as well as patient factors (pacemaker dependency and risk of intraoperative ventricular arrhythmias) and understand the details of the surgical procedure to be performed (including anatomical site, patient position during surgery [i.e. prone vs. supine], the type of electrocautery to be used, and the location of applications relative to the implanted device location).

When planning the strategy for device management in the perioperative period, key questions are:

1. Does the device need to be interrogated and checked preoperatively?
2. Does the device require intraoperative reprogramming?
3. Can a magnet be applied to the device?

All devices should be interrogated postoperatively. There is a considerable institutional variation in practice and physician preference. In general, the device should be checked prior to surgery if not checked electively in the preceding months or if battery longevity is unknown.

Pacemaker-dependent patients need either application of a magnet during delivery of diathermy pulses or reprogramming to a non-sensing mode (VOO/DOO) if diathermy above the umbilicus is planned or monopolar diathermy is used.

Implantable cardioverter-defibrillator therapies need to be turned off, preferably temporarily by a magnet taped over the device that can be taken away if ventricular tachyarrhythmia needs to be treated.<sup>244</sup> Unlike pacemakers, ICDs do not pace asynchronously during magnet application. In all these cases, it is important to assess that the magnet function of the ICD had not been previously disabled with the programmer, as possible with some devices. The patient needs to be monitored intraoperatively with external defibrillation equipment available in the room. Postoperative device reprogramming must ensure that tachycardia therapies are activated.

Procedures involving therapeutic radiation present particular risks to the CIED, are a common source of EMI, and may cause device reset. The device should be checked pre- and post-irradiation and careful attention paid to battery life and programmed parameters. The device may require shielding from the radiation beam and occasionally repositioning pretreatment. Elective external cardioversion can cause power-on-reset with only back-up function of the device or lead damage. It should always be applied in the anterior–posterior mode<sup>245</sup> since all cases of exit block have been reported in sternal–apical application of shock paddles. Radio-frequency ablation procedures may create EMI with effects similar to monopolar electrocautery.

## Management for magnetic resonance imaging scanning

Issues regarding the safety of magnetic resonance imaging (MRI) scanning for implanted electrical devices are complex and under discussion as device technology evolves in this field. There are MRI-conditional pacemaker and ICD systems. However, the type of MRI scanner (1.5 vs. 3.0 Tesla), body site to be scanned, type of CIED, the type of implanted leads, pacemaker dependency, and the presence of abandoned leads are only some of the issues to be considered. Recommendations on the use of MRI in CIED patients with specific algorithms and check lists should be considered.<sup>194,246</sup> Independently of the CIED labelled as ‘MRI conditional’, the physician is responsible for adequate monitoring of the patient (voice, ECG, and oxygen saturation) and the availability of a device programmer, external defibrillator, emergency equipment, and the presence of a trained staff for resuscitation. Patients with CKD are generally not considered appropriate for gadolinium-enhanced scanning because of the risk of gadolinium-induced systemic sclerosis.

## End-of-life issues

This section is summarized in Supplementary material online.


## The costs of chronic kidney disease and related organizational issues

Prevalence and incidence of both CKD and CVD increase with age; in western countries, progressive ageing of the population emphasizes the need to consider the problem of costs related to these diseases, which appear to assume the dimensions of public health threats.

Chronic kidney disease may remain silent for a long time, before reaching the most advanced stages, and at that point few opportunities exist to prevent adverse outcomes, cardiovascular complications, and need for dialysis, thus with an adverse impact on patients’ quality of life and significant costs for the healthcare system. In this regard, screening of patients at higher risk for CKD, those with heart failure, diabetes, hypertension, or a family history of hypertension, diabetes, or CKD, should be considered as attractive and potentially cost-saving. Management of the terminal stage of ESRD with dialysis is very expensive for healthcare systems. For dialysis, the reported costs are ~\$70 000 per year in the USA;<sup>247</sup> this huge financial impact is confirmed by the high tariffs for hospital reimbursement, in the range of \$700–1600 per week for dialysis, in a survey published in 2012 considering five European countries, Canada and the USA.<sup>248</sup> It is noteworthy that, in the USA, the cost of hospital dialysis has been assumed as the benchmark to define societal willingness to pay for a QALY (quality-adjusted life years), thus indicating that this expensive but effective treatment represents the upper boundary of what to consider affordable in cost-effectiveness and cost-utility analysis.<sup>249–251</sup>

In the cardiovascular field, and specifically in the management of rhythm disturbances, many devices, intervention, or treatments have a high, usually up-front, cost.<sup>249</sup> These treatments are targeted to reduce symptoms, morbidity, and mortality related to arrhythmic conditions, which, *per se*, induce substantial costs, usually in terms of disease-related hospitalizations.<sup>252</sup> For these treatments, Health Technology Assessments, corresponding to systematic, multidisciplinary assessments of clinical effectiveness and safety as well as cost-effectiveness of medical interventions, are increasingly used, for evaluating the clinical, economic, social, and organizational impacts of new technologies.<sup>249</sup> Chronic kidney disease has a substantial impact on many responses to treatments, complications, costs, and outcomes; therefore, it is an important determinant not only of clinical but also of economic evaluations. In this complex scenario, there is a need to collect additional data on the impact of CKD on patients’ outcomes in the ‘real world’, through prospective registries, since more advanced stages of renal impairment usually constitute a criterion of exclusion from randomized clinical trials.<sup>45–47</sup> Moreover, management of CKD in cardiac patients, and particularly in patients with heart failure and rhythm disturbances, may significantly benefit from a holistic approach based on collaborative, personalized, patient-centred care, with integration of different healthcare specialists, such as cardiologists and nephrologists. In this regard, the bidirectional interaction between the heart and the kidney (*Figure 2*) has been object of increasing interest in recent years, mainly focused on haemodynamic cardiac function and its acute or chronic deterioration,<sup>33</sup> but also issues related to rhythm disturbances and implantable electrical devices, as detailed in this review, which should be considered when planning new closer interactions between cardiologists and nephrologists.

Finally, even if the different organizations of care across western countries, as well as their different financial profiles, strongly influence the access to more advanced technologies,<sup>253</sup> increased efforts should be dedicated to assess the risk–benefit and cost–benefit of more advanced treatments, as well as preventive strategies in complex patients such as those with CKD or at risk of developing CKD.<sup>254</sup>



## Areas for further research

1. Heart disease, arrhythmias, and CKD have complex interactions, as shown in *Figure 2*. Therefore, the clinical and epidemiological impact of CKD in cardiac patients requires improved knowledge of the risk–benefit ratio of pharmacological therapies for cardiac disease and arrhythmias, as well as for device therapy, in the specific setting of the different stages of CKD. This can be accomplished by observational studies and registries, with extended follow-up (3–5 years) in order to assess the evolution of cardiac and renal functional status and the consequent impact on response to therapies and the occurrence of adverse outcomes (death, SCD, stroke and thromboembolism, acute coronary events, heart failure, syncope and ventricular tachyarrhythmias, acute kidney injury, CIED infections, etc.).
2. Prevention of thromboembolic events and stroke in patients with AF and more advanced CKD, with eGFR <25–30 mL/min, remains challenging since currently available NOACs, which all have a degree of renal excretion, have not been tested and validated in this setting. Testing and validation of alternatives to warfarin are needed, in view of the combined increased risk of stroke and thromboembolism, as well as major bleeding, associated with more advanced CKD. Moreover, the role of percutaneous left atrial appendage occlusion should also be carefully evaluated, in terms of risk–benefit ratio vs. usual care.
3. Well-controlled VKA therapy, with a high TTR (>70%), confers the best efficacy and safety in CKD patients<sup>84</sup> and strategies to

improve a TTR by education<sup>255</sup> or ‘flagging up’ patients less likely to achieve good TTRs with the SAME-TT<sub>2</sub>R<sub>2</sub> score<sup>102</sup> may help. This approach would need testing in large prospective observational cohorts or trial settings.

4. The traditional model of care delivery may be not adequate for clinical settings with a high degree of complexity, such as patients with cardiac diseases, rhythm disturbances, and advanced CKD. Therefore alternative, interdisciplinary methods for home care, with appropriate patient surveillance and monitoring,<sup>256,257</sup> should be validated (in terms of safety, effectiveness, and cost-effectiveness) also including the use of technology for remote monitoring, defining the appropriate role of all the stakeholders (family caregivers, nurses, physicians of the various disciplines involved, etc.).<sup>256,258</sup>

## Consensus statements

1. Since CKD, defined as a GFR <60 mL/min/1.73 m<sup>2</sup> for >3 months, is common (it exceeds 10% in the adult population with a substantial increase in the elderly) and increases the risk of cardiovascular morbidity and overall mortality, with profound influences on the risk–benefit profile of many treatments and interventions, it is appropriate to measure and monitor kidney function in any patient with a cardiac disease or rhythm disturbances, such as AF or sustained ventricular tachyarrhythmias.
  - The GFR can be estimated from the serum creatinine using a number of equations to give an eGFR, but clinician should remain aware of caveats for any estimating equation, which may influence the accuracy in a given individual patient and consider using additional tests (such as cystatin C or a clearance measurement) for confirmatory testing in specific circumstances when eGFR based on serum creatinine is less accurate.
2. In patients with CKD, arrhythmogenesis and the risk of SCD are related to many potentially concurring factors (rapid fluid and electrolyte shifts and particular acute or chronic hyperkalaemia or hypokalaemia, autonomic imbalance, prolongation and increased dispersion of ventricular repolarization, anaemia, acidosis, etc.) that need to be clinically evaluated, prevented, and corrected. Beta-blockers may be beneficial, although there is no direct evidence to support this.
3. Drug PK may be profoundly altered in CKD; therefore, drug dosages may need adjustment according to GFR, given the implications on prolonged half-life and reduced clearance of the drug, especially for drugs with a narrow therapeutic range, such as antiarrhythmic agents and anticoagulants. Specific considerations on removal of drugs by dialysis are required in patients treated by haemodialysis. In patients with AF, catheter-based ablation is increasingly used for rhythm control, and atrial fibrosis and persistent AF result to be the main determining factor of success, which overall, especially in haemodialysis patients, may require repeated procedures, as a consequence of the high recurrence rate of AF.
4. Patients with AF and associated CKD have a high risk of stroke and thromboembolism, as well as major bleeding, and these risks are particularly high in patients with renal replacement therapy, whether dialysis or renal transplantation. In patients with CKD, choice and monitoring of thromboprophylaxis deserves special clinical surveillance.
  - All the NOACs have a degree of renal excretion, and should not be used where severe renal impairment (creatinine clearance <25–30 mL/min) is evident. In this setting, warfarin is at present time the anticoagulant of choice.
  - The SAME-TT<sub>2</sub>R<sub>2</sub> score can be considered to identify patients less likely to achieve good TTRs while on VKAs, who should be targeted for more regular review and follow-up, with additional efforts (e.g. education) to improve the TTR.

5. In patients who need treatment with a CIED (a pacemaker, an ICD, or a device for CRT), clinical evaluation should consider that more advanced stages of CKD might be associated with effects similar to those observed in patients without CKD, but with a higher risk of adverse outcomes, including all-cause and cardiac mortality, all-cause and cardiovascular hospitalizations, and CIED infection. Therefore, individual assessment of the risk–benefit ratio of device therapy is needed. To minimize the risk of infections, in candidates to implant of a CIED, the access and routes for leads implantation should be decided on an individual basis, taking into account the increased risk for infection and vascular complications. In patients already implanted with a transvenous CIED, dialysis catheter should be avoided and contralateral access for arteriovenous fistula should be preferred.
6. Management of rhythm disturbances and CIEDs in patients with cardiac disease and CKD is complex and may require urgent and challenging decision-making (acute worsening of heart failure or renal function, electrical storms, surgical emergencies, etc.), thus requiring close collaboration between cardiologists, nephrologists, and other specialists.

## Supplementary material

Supplementary material is available at *Europace* online.

**EHRA Scientific Document Committee:** Gregory Y.H. Lip, (EHRA Scientific Documents Committee Chair), Bulent Gorenek, (EHRA Scientific Documents Committee Co-Chair), Christian Sticherling, Laurent Fauchier, Hein Heidebuchel, Angel Moya Mitjans, Marc A. Vos, Michele Brignole, Gheorghe-Andrei Dan, Michele Gulizia, Francisco Marin, Giuseppe Boriani, Deirdre Lane, and Irene Savelieva.

**Conflict of interest:** G.B. received speakers' fees (small amount) from Boehringer Ingelheim, Boston Scientific, Medtronic, and St Jude; G.-A.D. reported speaker fees (small amount) from Boehringer Ingelheim, Bayer, Pfizer, Servier, and ASTRA; D.A.L. received investigator-initiated educational grants from Bayer Healthcare, Boehringer Ingelheim, and Bristol Myers Squibb, and has also been on the speaker bureau for Boehringer Ingelheim, Bayer, and Bristol Myers Squibb/Pfizer; J.M. received research funding from St Jude Medical, Johnson and Johnson, and Biotronik; M.P.T. received consulting fees and honoraria from Medtronic, St Jude Medical, Precision Health Economics, Biotronik, and Gilead Sciences, and has grant support from Medtronic and iRhythm; G.Y.H.L. is a consultant for Bayer, Medtronic, Inc., Sanofi, BMS/Pfizer, Daiichi-Sankyo, and Boehringer Ingelheim, and has been a speaker for Bayer, BMS/Pfizer, Boehringer Ingelheim, Daiichi-Sankyo, and Medtronic, Inc.

## References

1. Eckardt KU, Coresh J, Devuyst O, Johnson RJ, Köttgen A, Levey AS *et al.* Evolving importance of kidney disease: from subspecialty to global health burden. *Lancet* 2013;**382**:158–69.
2. Levey AS, Coresh J. Chronic kidney disease. *Lancet* 2012;**379**:165–80.
3. Filippatos G, Farmakis D, Parisis J. Renal dysfunction and heart failure: things are seldom what they seem. *Eur Heart J* 2014;**35**:416–8.
4. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJ, Mann JF *et al.* Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. *Lancet* 2013;**382**:339–52.
5. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. *Kidney Int* 2013;**3**(Suppl):1–150.
6. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. *Nephron* 1976;**16**:31–41.
7. Michels WM, Grootendorst DG, Verduijn M, Elliott EG, Dekker FW, Krediet RT. Performance of the Cockcroft-Gault, MDRD, and new CKD-EPI formulas in relation to GFR, age, and body size. *Clin J Am Soc Nephrol* 2010;**5**:1003–9.
8. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation: Modification of Diet in Renal Disease Study Group. *Ann Intern Med* 1999;**130**:461–70.
9. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF III, Feldman HI *et al.* A new equation to estimate glomerular filtration rate. *Ann Intern Med* 2009;**150**:604–12.
10. Earley A, Miskulin D, Lamb EJ, Levey AS, Uhlig K. Estimating equations for glomerular filtration rate in the era of creatinine standardization: a systematic review. *Ann Intern Med* 2012;**156**:785–95.
11. Damman K, Voors AA, Navis G, van Veldhuisen DJ, Hillege HL. Current and novel renal biomarkers in heart failure. *Heart Fail Rev* 2012;**17**:241–50.
12. Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE *et al.* Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. *Lancet* 2010;**375**:2073–81.
13. van der Velde M, Matsushita K, Coresh J, Astor BC, Woodward M, Levey A *et al.* Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. *Kidney Int* 2011;**79**:1341–52.
14. Astor BC, Matsushita K, Gansevoort RT, van der Velde M, Woodward M, Levey AS *et al.* Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. *Kidney Int* 2011;**79**:1331–40.
15. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *Am J Kidney Dis* 2002;**39**(2 Suppl 1):S1–266.
16. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). *Kidney Int Suppl* 2009;**113**:S1–130.
17. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P *et al.* Prevalence of chronic kidney disease in the United States. *JAMA* 2007;**298**:2038–47.
18. Anandarajah S, Tai T, de Lusignan S, Stevens P, O'Donoghue D, Walker M *et al.* The validity of searching routinely collected general practice computer data to identify patients with chronic kidney disease (CKD): a manual review of 500 medical records. *Nephrol Dial Transplant* 2005;**20**:2089–96.
19. Hallan SI, Coresh J, Astor BC, Asberg A, Powe NR, Romundstad S *et al.* International comparison of the relationship of chronic kidney disease prevalence and ESRD risk. *J Am Soc Nephrol* 2006;**17**:2275–84.
20. Zhang L, Zhang P, Wang F, Zuo L, Zhou Y, Shi Y *et al.* Prevalence and factors associated with CKD: a population study from Beijing. *Am J Kidney Dis* 2008;**51**:373–84.
21. White SL, Polkinghorne KR, Atkins RC, Chadban SJ. Comparison of the prevalence and mortality risk of CKD in Australia using the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) Study GFR estimating equations: the AusDiab (Australian Diabetes, Obesity and Lifestyle) Study. *Am J Kidney Dis* 2010;**55**:660–70.
22. Imai E, Horio M, Watanabe T, Iseki K, Yamagata K, Hara S *et al.* Prevalence of chronic kidney disease in the Japanese general population. *Clin Exp Nephrol* 2009;**13**:621–30.
23. Zhang QL, Rothenbacher D. Prevalence of chronic kidney disease in population-based studies: systematic review. *BMC Public Health* 2008;**8**:117.
24. Otero A, de Francisco A, Gayoso P, Garcia F, Group ES. Prevalence of chronic renal disease in Spain: results of the EPIRCE study. *Nefrologia* 2010;**30**:78–86.
25. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. *N Engl J Med* 2004;**351**:1296–305.
26. Van Biesen W, De Bacquer D, Verbeke F, Delanghe J, Lameire N, Vanholder R. The glomerular filtration rate in an apparently healthy population and its relation with cardiovascular mortality during 10 years. *Eur Heart J* 2007;**28**:478–83.
27. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. *Arch Intern Med* 2004;**164**:659–63.
28. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. *Am J Kidney Dis* 1998;**32**(5 Suppl 3):S112–119.
29. U.S. Renal Data System. *USRDS 2006 Annual Data Report: Atlas of End-Stage Renal Disease in the United States*. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2006.

30. Mafham M, Emberson J, Landray MJ, Wen CP, Baigent C. Estimated glomerular filtration rate and the risk of major vascular events and all-cause mortality: a meta-analysis. *PLoS ONE* 2011;**6**:e25920.
31. Chue CD, Townend JN, Steeds RP, Ferro CJ. Arterial stiffness in chronic kidney disease: causes and consequences. *Heart* 2010;**96**:817–23.
32. Moody WE, Edwards NC, Chue CD, Ferro CJ, Townend JN. Arterial disease in chronic kidney disease. *Heart* 2013;**99**:365–72.
33. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. *J Am Coll Cardiol* 2008;**52**:1527–39.
34. Cruz DN, Schmidt-Ott KM, Vescovo G, House AA, Kellum JA, Ronco C et al. Pathophysiology of cardiorenal syndrome type 2 in stable chronic heart failure: workgroup statements from the eleventh consensus conference of the Acute Dialysis Quality Initiative (ADQI). *Contrib Nephrol* 2013;**182**:117–36.
35. Tumlin JA, Costanzo MR, Chawla LS, Herzog CA, Kellum JA, McCullough PA et al. Cardiorenal syndrome type 4: insights on clinical presentation and pathophysiology from the eleventh consensus conference of the Acute Dialysis Quality Initiative (ADQI). *Contrib Nephrol* 2013;**182**:158–73.
36. Heywood JT, Fonarow GC, Costanzo MR, Mathur VS, Wigneswaran JR, Wynne J et al. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. *J Card Fail* 2007;**13**:422–30.
37. Hebert K, Dias A, Delgado MC, Franco E, Tamariz L, Steen D et al. Epidemiology and survival of the five stages of chronic kidney disease in a systolic heart failure population. *Eur J Heart Fail* 2010;**12**:861–5.
38. Cruz DN, Bagshaw SM. Heart-kidney interaction: epidemiology of cardiorenal syndromes. *Int J Nephrol* 2010;**2011**:351291.
39. Crews DC, Plantinga LC, Miller ER III, Saran R, Hedgeman E, Saydah SH et al. Prevalence of chronic kidney disease in persons with undiagnosed or prehypertension in the United States. *Hypertension* 2010;**55**:1102–9.
40. Zoni-Berisso M, Lercari F, Carazza T, Domenicucci S. Epidemiology of atrial fibrillation: European perspective. *Clin Epidemiol* 2014;**6**:213–20.
41. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. *JAMA* 2001;**285**:2370–5.
42. Boriani G, Diemberger I, Martignani C, Biffi M, Branzi A. The epidemiological burden of atrial fibrillation: a challenge for clinicians and healthcare systems. *Eur Heart J* 2006;**27**:893–4.
43. Alonso A, Lopez FL, Matsushita K, Loehr LR, Agarwal SK, Chen LY et al. Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. *Circulation* 2011;**123**:2946–53.
44. McManus DD, Rienstra M, Benjamin EJ. An update on the prognosis of patients with atrial fibrillation. *Circulation* 2012;**126**:e143–6.
45. Lip GY, Laroche C, Boriani G, Cimaglia P, Dan GA, Santini M et al. Sex-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro Observational Research Programme Pilot survey on Atrial Fibrillation. *Europace* 2015;**17**:24–31.
46. Boriani G, Laroche C, Diemberger I, Fantecchi E, Popescu MI, Rasmussen LH et al. Asymptomatic atrial fibrillation: clinical correlates, management and outcomes in the EORP-AF Pilot General Registry. *Am J Med* 2015;**128**:509–18.
47. Lip GY, Laroche C, Popescu MI, Rasmussen LH, Vitali-Serdoz L, Dan GA et al. Heart failure in patients with atrial fibrillation in Europe: a report from the EURObservational Research Programme Pilot survey on Atrial Fibrillation. *Eur J Heart Fail* 2015; doi: 10.1002/ehf.254.
48. Watanabe H, Watanabe T, Sasaki S, Nagai K, Roden DM, Aizawa Y. Close bidirectional relationship between chronic kidney disease and atrial fibrillation: the Niigata preventive medicine study. *Am Heart J* 2009;**158**:629–36.
49. Wetmore JB, Mahnen JD, Rigler SK, Ellerbeck EF, Mukhopadhyay P, Spertus JA et al. The prevalence of and factors associated with chronic atrial fibrillation in Medicare/Medicaid-eligible dialysis patients. *Kidney Int* 2012;**81**:469–76.
50. Goldstein BA, Arce CM, Hlatky MA, Turakhia M, Setoguchi S, Winkelmayer WC. Trends in the incidence of atrial fibrillation in older patients initiating dialysis in the United States. *Circulation* 2012;**126**:2293–301.
51. Winkelmayer WC, Liu J, Patrick AR, Setoguchi S, Choudhry NK. Prevalence of atrial fibrillation and warfarin use in older patients receiving hemodialysis. *J Nephrol* 2012;**25**:341–53.
52. Ananthapanyasut W, Napan S, Rudolph EH, Harindhanavudhi T, Ayash H, Guglielmi KE et al. Prevalence of atrial fibrillation and its predictors in nondialysis patients with chronic kidney disease. *Clin J Am Soc Nephrol* 2010;**5**:173–81.
53. Soliman EZ, Prineas RJ, Go AS, Xie D, Lash JP, Rahman M et al. Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC). *Am Heart J* 2010;**159**:1102–7.
54. Baber U, Howard VJ, Halperin JL, Soliman EZ, Zhang X, McClellan W et al. Association of chronic kidney disease with atrial fibrillation among adults in the United States: REasons for Geographic and Racial Differences in Stroke (REGARDS) Study. *Circ Arrhythm Electrophysiol* 2011;**4**:26–32.
55. Olesen JB, Lip GY, Kamper AL, Hommel K, Kober L, Lane DA et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. *N Engl J Med* 2012;**367**:625–35.
56. Wong JA, Goodman SG, Yan RT, Wald R, Bagnall AJ, Welsh RC et al. Temporal management patterns and outcomes of non-ST elevation acute coronary syndromes in patients with kidney dysfunction. *Eur Heart J* 2009;**30**:549–57.
57. Fox CS, Muntner P, Chen AY, Alexander KP, Roe MT, Cannon CP et al. Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry. *Circulation* 2010;**121**:357–65.
58. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. *Circulation* 2003;**108**:2154–69.
59. Fox CS, Matsushita K, Woodward M, Bilo HJ, Chalmers J, Heerspink HJ et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. *Lancet* 2012;**380**:1662–73.
60. Mahmoodi BK, Matsushita K, Woodward M, Blankstijn PJ, Cirillo M, Ohkubo T et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis. *Lancet* 2012;**380**:1649–61.
61. Foley RN, Murray AM, Li S, Herzog CA, McBean AM, Eggers PW et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. *J Am Soc Nephrol* 2005;**16**:489–95.
62. Rahman M, Pressel S, Davis BR, Nwachuku C, Wright JT Jr, Whelton PK et al. Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. *Ann Intern Med* 2006;**144**:172–80.
63. Menon V, Wang X, Sarnak MJ, Hunsicker LH, Madero M, Beck GJ et al. Long-term outcomes in nondiabetic chronic kidney disease. *Kidney Int* 2008;**73**:1310–5.
64. Hunsicker LG, Adler S, Caggiula A, England BK, Greene T, Kusek JW et al. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. *Kidney Int* 1997;**51**:1908–19.
65. Haroun MK, Jaar BG, Hoffman SC, Comstock GW, Klag MJ, Coresh J. Risk factors for chronic kidney disease: a prospective study of 23,534 men and women in Washington County, Maryland. *J Am Soc Nephrol* 2003;**14**:2934–41.
66. Stengel B, Tarver-Carr ME, Powe NR, Eberhardt MS, Brancati FL. Lifestyle factors, obesity and the risk of chronic kidney disease. *Epidemiology* 2003;**14**:479–8.
67. Tangri N, Stevens LA, Griffith J, Tighiouart H, Djurdjev O, Naimark D et al. A predictive model for progression of chronic kidney disease to kidney failure. *JAMA* 2011;**305**:1553–9.
68. Bansal N, Alce D, Hsu CY, Ordonez JD, Marcus GM, Go AS. Incident atrial fibrillation and risk of end-stage renal disease in adults with chronic kidney disease. *Circulation* 2013;**127**:569–74.
69. Chiu PF, Huang CH, Liou HH, Wu CL, Chang C, Chang CC et al. Lower-dose warfarin delays renal progression and prolongs patient survival in patients with stage 3–5 chronic kidney disease and nonvalvular atrial fibrillation: a 12-year follow-up study. *Int J Clin Pharmacol Ther* 2014;**52**:504–8.
70. Chang CC, Liou HH, Wu CL, Chang CB, Chang YJ, Chiu PF et al. Warfarin slows deterioration of renal function in elderly patients with chronic kidney disease and atrial fibrillation. *Clin Interv Aging* 2013;**8**:523–9.
71. Roberts PR, Green D. Arrhythmias in chronic kidney disease. *Heart* 2011;**97**:766–73.
72. Poulikakos D, Banerjee D, Malik M. Risk of sudden cardiac death in chronic kidney disease. *J Cardiovasc Electrophysiol* 2014;**25**:222–31.
73. Middleton JP. Predisposition to arrhythmias: electrolytes, uremic fibrosis, other factors. *Semin Dial* 2011;**24**:287–9.
74. El-Sherif N, Turitto G. Electrolyte disturbances and arrhythmogenesis. *Cardiol J* 2011;**18**:233–45.
75. Turakhia MP, Schiller NB, Whooley MA. Prognostic significance of increased left ventricular mass index to mortality and sudden death in patients with stable coronary heart disease (from the Heart and Soul Study). *Am J Cardiol* 2008;**102**:1131–5.
76. Zaza A. Serum potassium and arrhythmias. *Europace* 2009;**11**:421–2.
77. Matzke GR, Aronoff GR, Atkinson AJ Jr, Bennett WM, Decker BS, Eckardt KU et al. Drug dosing consideration in patients with acute and chronic kidney disease—a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). *Kidney Int* 2011;**80**:1122–37.



78. Kaski JC, Baker S, Hayward C, Khong TK, Mahida S, Tamargo J (eds). *Drugs in Cardiology: a Comprehensive Guide to Cardiovascular Pharmacotherapy*. London, UK: Oxford University Press; 2010.
79. Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. *Europace* 2013;**15**:625–51.
80. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation—developed with the special contribution of the European Heart Rhythm Association. *Europace* 2012;**14**:1385–413.
81. Providência R, Marijon E, Boveda S, Barra S, Narayanan K, Le Heuzey JY et al. Meta-analysis of the influence of chronic kidney disease on the risk of thromboembolism among patients with nonvalvular atrial fibrillation. *Am J Cardiol* 2014;**114**:646–53.
82. Shah M, Avgil Tsadok M, Jackevicius CA, Essebag V, Eisenberg MJ, Rahme E et al. Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis. *Circulation* 2014;**129**:1196–203.
83. Kooiman J, van Rein N, Spaans B, van Beers KA, Bank JR, van de Peppel W et al. Efficacy and safety of vitamin K-antagonists (VKA) for atrial fibrillation in non-dialysis dependent chronic kidney disease. *PLoS ONE* 2014;**9**:e94420.
84. Friberg L, Benson L, Lip GY. Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: the Swedish Atrial Fibrillation Cohort study. *Eur Heart J* 2015;**36**:297–306.
85. Chao TF, Liu CJ, Wang KL, Lin YJ, Chang SL, Lo LW et al. Incidence and prediction of ischaemic stroke among atrial fibrillation patients with end-stage renal disease requiring dialysis. *Heart Rhythm* 2014;**11**:1752–9.
86. Roldán V, Marín F, Fernández H, Manzano-Fernandez S, Gallego P, Valdés M et al. Renal impairment in a 'real-life' cohort of anticoagulated patients with atrial fibrillation (implications for thromboembolism and bleeding). *Am J Cardiol* 2013;**111**:1159–64.
87. Banerjee A, Fauchier L, Yourc'h P, Andres CR, Taillandier S, Halimi JM et al. Renal impairment and ischemic stroke risk assessment in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. *J Am Coll Cardiol* 2013;**61**:2079–87.
88. Apostolakis S, Guo Y, Lane DA, Buller H, Lip GYH. Renal function and outcomes in anticoagulated patients with non-valvular atrial fibrillation: the AMADEUS trial. *Eur Heart J* 2013;**34**:3572–9.
89. Banerjee A, Fauchier L, Yourc'h P, Andres CR, Taillandier S, Halimi JM et al. A prospective study of estimated glomerular filtration rate and outcomes in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. *Chest* 2014;**145**:1370–82.
90. Go AS, Fang MC, Udaltsova N, Chang Y, Pomernacki NK, Borowsky L et al. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. *Circulation* 2009;**119**:1363–9.
91. Hijazi Z, Hohnloser SH, Oldgren J, Andersson U, Connolly SJ, Eikelboom JW et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. *Circulation* 2014;**129**:961–70.
92. Eikelboom JW, Connolly SJ, Gao P, Paolasso E, De Caterina R, Husted S et al. Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease. *J Stroke Cerebrovasc Dis* 2012;**21**:429–35.
93. Hohnloser SH, Hijazi Z, Thomas L, Alexander JH, Amerena J, Hanna M et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. *Eur Heart J* 2012;**33**:2821–30.
94. Fox KA, Piccini JP, Wojdyla D, Becker RC, Halperin JL, Nessel CC et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. *Eur Heart J* 2011;**32**:2387–94.
95. Piccini JP, Stevens SR, Chang Y, Singer DE, Lokhnygina Y, Go AS et al. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. *Circulation* 2013;**127**:224–32.
96. Singer DE, Chang Y, Borowsky LH, Fang MC, Pomernacki NK, Udaltsova N et al. A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score. *J Am Heart Assoc* 2013;**2**:e000250.
97. Kornej J, Hindricks G, Kosiuk J, Arya A, Sommer P, Husser D et al. Comparison of CHADS2, R2CHADS2, and CHA2DS2-VASc scores for the prediction of rhythm outcomes after catheter ablation of atrial fibrillation: the Leipzig Heart Center AF Ablation Registry. *Circ Arrhythm Electrophysiol* 2014;**7**:281–7.
98. Chao TF, Liu CJ, Wang KL, Lin YJ, Chang SL, Lo LW et al. Using the CHA2DS2-VASc score for refining stroke risk stratification in 'low-risk' Asian patients with atrial fibrillation. *J Am Coll Cardiol* 2014;**64**:1658–65.
99. Lip GY, Nielsen PB, Skjøth F, Lane DA, Rasmussen LH, Larsen TB. The value of the European society of cardiology guidelines for refining stroke risk stratification in patients with atrial fibrillation categorized as low risk using the anticoagulation and risk factors in atrial fibrillation stroke score: a nationwide cohort study. *Chest* 2014;**146**:1337–46.
100. Roldán V, Marín F, Manzano-Fernandez S, Fernández H, Gallego P, Valdés M et al. Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation? *Thromb Haemost* 2013;**109**:956–60.
101. Guo Y, Wang H, Zhao X, Zhang Y, Zhang D, Ma J et al. Relation of renal dysfunction to the increased risk of stroke and death in female patients with atrial fibrillation. *Int J Cardiol* 2013;**168**:1502–8.
102. Apostolakis S, Sullivan RM, Olshansky B, Lip GY. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAME-TT<sub>2</sub>R<sub>2</sub> score. *Chest* 2013;**144**:1555–63.
103. De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F et al. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis—Task Force on Anticoagulants in Heart Disease. *Thromb Haemost* 2013;**110**:1087–107.
104. Gallego P, Roldán V, Marín F, Romera M, Valdés M, Vicente V et al. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. *Thromb Haemost* 2013;**110**:1189–98.
105. Pisters R, Lane DA, Nieuwlaar R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. *Chest* 2010;**138**:1093–100.
106. Lip GY, Frison L, Grind M, SPORTIF Investigators. Effect of hypertension on anticoagulated patients with atrial fibrillation. *Eur Heart J* 2007;**28**:752–9.
107. Lip GY, Frison L, Grind M. Angiotensin converting enzyme inhibitor and angiotensin receptor blockade use in relation to outcomes in anticoagulated patients with atrial fibrillation. *J Intern Med* 2007;**261**:577–86.
108. Verdecchia P, Reboldi G, Di Pasquale G, Mazzotta G, Ambrosio G, Yang S et al. Prognostic usefulness of left ventricular hypertrophy by electrocardiography in patients with atrial fibrillation (from the Randomized Evaluation of Long-Term Anticoagulant Therapy Study). *Am J Cardiol* 2014;**113**:669–75.
109. Verdecchia P, Reboldi G, Gattobigio R, Bentivoglio M, Borgioni C, Angeli F et al. Atrial fibrillation in hypertension: predictors and outcome. *Hypertension* 2003;**41**:218–23.
110. Konecny T, Park JY, Somers KR, Konecny D, Orban M, Soucek F et al. Relation of chronic obstructive pulmonary disease to atrial and ventricular arrhythmias. *Am J Cardiol* 2014;**114**:272–7.
111. Ganga HV, Nair SU, Puppala VK, Miller WL. Risk of new-onset atrial fibrillation in elderly patients with the overlap syndrome: a retrospective cohort study. *J Geriatr Cardiol* 2013;**10**:129–34.
112. Chao TF, Liu CJ, Chen SJ, Wang KL, Lin YJ, Chang SL et al. Incidence and risk of atrial fibrillation in sleep-disordered breathing without coexistent systemic disease. *Circ J* 2014;**78**:2182–7.
113. Yazdan-Ashoori P, Baranchuk A. Obstructive sleep apnea may increase the risk of stroke in AF patients: refining the CHADS2 score. *Int J Cardiol* 2011;**146**:131–3.
114. Goyal SK, Wang L, Upender R, Darbar D, Monahan K. Severity of obstructive sleep apnea influences the effect of genotype on response to anti-arrhythmic drug therapy for atrial fibrillation. *J Clin Sleep Med* 2014;**10**:503–7.
115. Sano F, Ohira T, Kitamura A, Imano H, Cui R, Kiyama M et al. Heavy alcohol consumption and risk of atrial fibrillation. The Circulatory Risk in Communities Study (CIRCS). *Circ J* 2014;**78**:955–61.
116. Larsson SC, Drca N, Wolk A. Alcohol consumption and risk of atrial fibrillation: a prospective study and dose-response meta-analysis. *J Am Coll Cardiol* 2014;**64**:281–9.
117. Overvad TF, Rasmussen LH, Skjøth F, Overvad K, Albertsen IE, Lane DA et al. Alcohol intake and prognosis of atrial fibrillation. *Heart* 2013;**99**:1093–9.
118. Overvad TF, Rasmussen LH, Skjøth F, Overvad K, Lip GY, Larsen TB. Body mass index and adverse events in patients with incident atrial fibrillation. *Am J Med* 2013;**126**:640.
119. Abed HS, Wittert GA, Leong DP, Shirazi MG, Bahrami B, Middeldorp ME et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. *JAMA* 2013;**310**:2050–60.
120. Parekh RS, Carroll CE, Wolfe RA, Port FK. Cardiovascular mortality in children and young adults with end-stage kidney disease. *J Pediatr* 2002;**141**:191–7.
121. Herzog CA, Li S, Weinhandl ED, Strief JW, Collins AJ, Gilbertson DT. Survival of dialysis patients after cardiac arrest and the impact of implantable cardioverter defibrillators. *Kidney Int* 2005;**68**:818–25.

122. Foley RN. Clinical epidemiology of cardiac disease in dialysis patients: left ventricular hypertrophy, ischemic heart disease, and cardiac failure. *Semin Dial* 2003;**16**:111–7.
123. Parekh RS, Plantinga LC, Kao WH, Meoni LA, Jaar BG, Fink NE et al. The association of sudden cardiac death with inflammation and other traditional risk factors. *Kidney Int* 2008;**74**:1335–42.
124. Wang AY, Lam CW, Chan IH, Wang M, Lui SF, Sanderson JE. Sudden cardiac death in end-stage renal disease patients: a 5-year prospective analysis. *Hypertension* 2010;**56**:210–6.
125. Genovesi S, Rossi E, Nava M, Riva H, De Franceschi S, Fabbrini P et al. A case series of chronic haemodialysis patients: mortality, sudden death, and QT interval. *Eurpace* 2013;**15**:1025–33.
126. Goldenberg I, Moss AJ, McNitt S, Zareba W, Andrews ML, Hall WJ et al. Relations among renal function, risk of sudden cardiac death, and benefit of the implanted cardiac defibrillator in patients with ischemic left ventricular dysfunction. *Am J Cardiol* 2006;**98**:485–90.
127. Saxon LA, Bristow MR, Boehmer J, Krueger S, Kass DA, De Marco T et al. Predictors of sudden cardiac death and appropriate shock in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Trial. *Circulation* 2006;**114**:2766–72.
128. Deo R, Lin F, Vittinghoff E, Tseng ZH, Hulley SB, Shlipak MG. Kidney dysfunction and sudden cardiac death among women with coronary heart disease. *Hypertension* 2008;**51**:1578–82.
129. Pun PH, Smarz TR, Honeycutt EF, Shaw LK, Al-Khatib SM, Middleton JP. Chronic kidney disease is associated with increased risk of sudden cardiac death among patients with coronary artery disease. *Kidney Int* 2009;**76**:652–8.
130. Davis TR, Young BA, Eisenberg MS, Rea TD, Copass MK, Cobb LA. Outcome of cardiac arrests attended by emergency medical services staff at community outpatient dialysis centers. *Kidney Int* 2008;**73**:933–9.
131. Whitman IR, Feldman HI, Deo R. CKD and sudden cardiac death: epidemiology, mechanisms, and therapeutic approaches. *J Am Soc Nephrol* 2012;**23**:1929–39.
132. de Bie MK, Buiten MS, Rabelink TJ, Jukema JW. How to reduce sudden cardiac death in patients with renal failure. *Heart* 2012;**98**:335–41.
133. Edwards NC, Steeds RP, Ferro CJ, Townend JN. The treatment of coronary artery disease in patients with chronic kidney disease. *QJM* 2006;**99**:723–36.
134. Charytan D, Mauri L, Agarwal A, Servoss S, Scirica B, Kuntz RE. The use of invasive cardiac procedures after acute myocardial infarction in long-term dialysis patients. *Am Heart J* 2006;**152**:558–64.
135. Cheung AK, Sarnak MJ, Yan G, Berkoben M, Heyka R, Kaufman A et al. Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study. *Kidney Int* 2004;**65**:2380–9.
136. Glasscock RJ, Pecoits-Filho R, Barberato SH. Left ventricular mass in chronic kidney disease and ESRD. *Clin J Am Soc Nephrol* 2009;**4**(Suppl 1):S79–91.
137. Middleton RJ, Parfrey PS, Foley RN. Left ventricular hypertrophy in the renal patient. *J Am Soc Nephrol* 2001;**12**:1079–84.
138. Paoletti E, Bellino D, Cassottana P, Rolla D, Cannella G. Left ventricular hypertrophy in nondiabetic predialysis CKD. *Am J Kidney Dis* 2005;**46**:320–7.
139. Edwards NC, Moody WE, Chue CD, Ferro CJ, Townend JN, Steeds RP. Defining the natural history of uremic cardiomyopathy in chronic kidney disease: the role of cardiovascular magnetic resonance. *JACC Cardiovasc Imaging* 2014;**7**:703–14.
140. Jaroszynski A, Czekajka-Chechab E, Drelich-Zbroja A, Zapolski T, Ksiazek A. Spatial QRS-T angle in peritoneal dialysis patients: association with carotid artery atherosclerosis, coronary artery calcification and troponin T. *Nephrol Dial Transplant* 2009;**24**:1003–8.
141. de Bie MK, Koopman MG, Gaasbeek A, Dekker FW, Maan AC, Swenne CA et al. Incremental prognostic value of an abnormal baseline spatial QRS-T angle in chronic dialysis patients. *Eurpace* 2013;**15**:290–6.
142. Converse RL Jr, Jacobsen TN, Toto RD, Jost CM, Cosentino F, Fouad-Tarazi F et al. Sympathetic overactivity in patients with chronic renal failure. *N Engl J Med* 1992;**327**:1912–8.
143. Ye S, Gamburd M, Mozayani P, Koss M, Campese VM. A limited renal injury may cause a permanent form of neurogenic hypertension. *Am J Hypertens* 1998;**11**(6 Pt 1):723–8.
144. Zoccali C, Mallamaci F, Parlongo S, Cutrupi S, Benedetto FA, Tripepi G et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. *Circulation* 2002;**105**:1354–9.
145. Bleyer AJ, Russell GB, Satko SG. Sudden and cardiac death rates in hemodialysis patients. *Kidney Int* 1999;**55**:1553–9.
146. Bleyer AJ, Hartman J, Brannon PC, Reeves-Daniel A, Satko SG, Russell G. Characteristics of sudden death in hemodialysis patients. *Kidney Int* 2006;**69**:2268–73.
147. Foley RN, Gilbertson DT, Murray T, Collins AJ. Long interdialytic interval and mortality among patients receiving hemodialysis. *N Engl J Med* 2011;**365**:1099–107.
148. Perl J, Chan CT. Timing of sudden death relative to the hemodialysis procedure. *Nat Clin Pract Nephrol* 2006;**2**:668–9.
149. de Bie MK, van Dam B, Gaasbeek A, van Buren M, van Erven L, Bax JJ et al. The current status of interventions aiming at reducing sudden cardiac death in dialysis patients. *Eur Heart J* 2009;**30**:1559–64.
150. Karnik JA, Young BS, Lew NL, Herget M, Dubinsky C, Lazarus JM et al. Cardiac arrest and sudden death in dialysis units. *Kidney Int* 2001;**60**:350–7.
151. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. *Lancet* 1999;**353**:9–13.
152. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). *Lancet* 1999;**353**:2001–7.
153. Brophy JM, Joseph L, Rouleau JL. Beta-blockers in congestive heart failure. A Bayesian meta-analysis. *Ann Intern Med* 2001;**134**:550–60.
154. Charytan D, Kuntz RE. The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease. *Kidney Int* 2006;**70**:2021–30.
155. Coca SG, Krumholz HM, Garg AX, Parikh CR. Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. *JAMA* 2006;**296**:1377–84.
156. Chonchol M, Benderly M, Goldbourt U. Beta-blockers for coronary heart disease in chronic kidney disease. *Nephrol Dial Transplant* 2008;**23**:2274–9.
157. Tonelli M, Moye L, Sacks FM, Kiberd B, Curhan G, Cholesterol and Recurrent Events Trial Investigators. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. *Ann Intern Med* 2003;**138**:98–104.
158. Navaneethan SD, Pansini F, Perkovic V, Manno C, Pellegrini F, Johnson DW et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. *Cochrane Database Syst Rev* 2009;**2**:CD007784.
159. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. *Lancet* 2011;**377**:2181–92.
160. Tomaschitz A, Pilz S, Ritz E, Grammer T, Drechsler C, Boehm BO et al. Association of plasma aldosterone with cardiovascular mortality in patients with low estimated GFR: the Ludwigshafen Risk and Cardiovascular Health (LURIC) Study. *Am J Kidney Dis* 2011;**57**:403–14.
161. Pun PH, Lehrich RW, Smith SR, Middleton JP. Predictors of survival after cardiac arrest in outpatient hemodialysis clinics. *Clin J Am Soc Nephrol* 2007;**2**:491–500.
162. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. *N Engl J Med* 1999;**341**:709–17.
163. Pun PH, Lehrich RW, Honeycutt EF, Herzog CA, Middleton JP. Modifiable risk factors associated with sudden cardiac arrest within hemodialysis clinics. *Kidney Int* 2011;**79**:218–27.
164. Culleton BF, Walsh M, Klarenbach SW, Mortis G, Scott-Douglas N, Quinn RR et al. Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial. *JAMA* 2007;**298**:1291–9.
165. Chertow GM, Levin NW, Beck GJ, Depner TA, Eggers PW, Gassman JJ et al. In-center hemodialysis six times per week versus three times per week. *N Engl J Med* 2010;**363**:2287–300.
166. Wann LS, Curtis AB, January CT, Ellenbogen KA, Lowe JE, Estes NA 3rd et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation* 2011;**123**:104–23.
167. Nimmo C, Wright M, Goldsmith D. Management of atrial fibrillation in chronic kidney disease: double trouble. *Am Heart J* 2013;**166**:230–9.
168. Palmer BF, Henrich WL. Recent advances in the prevention and management of intradialytic hypotension. *J Am Soc Nephrol* 2008;**19**:8–11.
169. Stefansson BV, Brunelli SM, Cabrera C, Rosenbaum D, Anum E, Ramakrishnan K et al. Intradialytic hypotension and risk of cardiovascular disease. *Clin J Am Soc Nephrol* 2014;**9**:2124–32.
170. Henderson LW. Symptomatic intradialytic hypotension and mortality: an opinionated review. *Semin Dial* 2012;**25**:320–5.
171. Flythe JE, Xue H, Lynch KE, Curhan GC, Brunelli SM. Association of mortality risk with various definitions of intradialytic hypotension. *J Am Soc Nephrol* 2015;**26**:724–34.
172. Davenport A, Cox C, Thuraisingham R. Achieving blood pressure targets during dialysis improves control but increases intradialytic hypotension. *Kidney Int* 2008;**73**:759–64.
173. Agarwal R, Alborzi P, Satyan S, Light RP. Dry-weight reduction in hypertensive hemodialysis patients (DRIP): a randomized, controlled trial. *Hypertension* 2009;**53**:500–7.
174. Lip GY, Tse HF, Lane DA. Atrial fibrillation. *Lancet* 2012;**379**:648–61.

175. Boriani G, Biffi M, Diemberger I, Martignani C, Branzi A. Rate control in atrial fibrillation: choice of treatment and assessment of efficacy. *Drugs* 2003;**63**:1489–509.
176. Kirchhof P, Breithardt G, Aliot E, Al Khatib S, Apostolakis S, Auricchio A *et al*. Personalized management of atrial fibrillation: proceedings from the fourth Atrial Fibrillation competence NETWORK/European Heart Rhythm Association consensus conference. *Europace* 2013;**15**:1540–56.
177. Van Gelder IC, Groeneweld HF, Crijns HJ, Tuininga YS, Tijssen JG, Alings AM *et al*. Lenient versus strict rate control in patients with atrial fibrillation. *N Engl J Med* 2010;**362**:1363–73.
178. Talajic M, Khairy P, Levesque S, Connolly SJ, Dorian P, Dubuc M *et al*. Maintenance of sinus rhythm and survival in patients with heart failure and atrial fibrillation. *J Am Coll Cardiol* 2010;**55**:1796–802.
179. Szczech LA. Atrial fibrillation: the beat is faster than the answers. *Kidney Int* 2012;**81**:432–3.
180. Ng KP, Edwards NC, Lip GY, Townend JN, Ferro CJ. Atrial fibrillation in CKD: balancing the risks and benefits of anticoagulation. *Am J Kidney Dis* 2013;**62**:615–32.
181. Navaravong L, Barakat M, Burgon N, Mahnkopf C, Koopmann M, Ranjan R *et al*. Improvement in estimated glomerular filtration rate in patients with chronic kidney disease undergoing catheter ablation for atrial fibrillation. *J Cardiovasc Electrophysiol* 2015;**26**:21–7.
182. Wilber DJ, Pappone C, Neuzil P, De Paola A, Marchlinski F, Natale A *et al*. Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. *JAMA* 2010;**303**:333–40.
183. Haegeli LM, Calkins H. Catheter ablation of atrial fibrillation: an update. *Eur Heart J* 2014;**35**:2454–9.
184. Naruse Y, Tada H, Sekiguchi Y, Machino T, Ozawa M, Yamasaki H *et al*. Concomitant chronic kidney disease increases the recurrence of atrial fibrillation after catheter ablation of atrial fibrillation: a mid-term follow-up. *Heart Rhythm* 2011;**8**:335–41.
185. Sairaku A, Yoshida Y, Kamiya H, Tatematsu Y, Nanasato M, Hirayama H *et al*. Outcomes of ablation of paroxysmal atrial fibrillation in patients on chronic hemodialysis. *J Cardiovasc Electrophysiol* 2012;**23**:1289–94.
186. Hayashi M, Kaneko S, Shimano M, Ohashi T, Kubota R, Takeshita K *et al*. Efficacy and safety of radiofrequency catheter ablation for atrial fibrillation in chronic hemodialysis patients. *Nephrol Dial Transplant* 2014;**29**:160–7.
187. Takigawa M, Kuwahara T, Takahashi A, Kobori A, Takahashi Y, Okubo K *et al*. The impact of haemodialysis on the outcomes of catheter ablation in patients with paroxysmal atrial fibrillation. *Europace* 2014;**16**:327–34.
188. Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, Griffith JL *et al*. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. *J Am Soc Nephrol* 2004;**15**:1307–15.
189. Kristensen SD, Knuuti J, Saraste A, Anker S, Bøtker HE, Hert SD *et al*. 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: the Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). *Eur Heart J* 2014;**35**:2383–431.
190. Shastri S, Sarnak MJ. Cardiovascular disease and CKD: core curriculum 2010. *Am J Kidney Dis* 2010;**56**:399–417.
191. Trainor D, Borthwick E, Ferguson A. Perioperative management of the hemodialysis patient. *Semin Dial* 2011;**24**:314–26.
192. Lee TH, Marcantonio ER, Mangione CM, Thomas EJ, Polanczyk CA, Cook EF *et al*. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. *Circulation* 1999;**100**:1043–9.
193. KDOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. *Am J Kidney Dis* 2005;**45**(4 Suppl 3):S1–153.
194. Brignole M, Auricchio A, Baron-Esquivias G, Bordachar P, Boriani G, Breithardt OA *et al*. 2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC)/European Society of Cardiology (ESC); European Heart Rhythm Association (EHRA). *Europace* 2013;**15**:1070–118.
195. Hercé B, Nazeyrollas P, Lesaffre F, Sandras R, Chabert JP, Martin A *et al*. Risk factors for infection of implantable cardiac devices: data from a registry of 2496 patients. *Europace* 2013;**15**:66–70.
196. Vanerio G, García C, González C, Ferreira A. Mortality in patients on renal replacement therapy and permanent cardiac pacemakers. *Int J Nephrol* 2014;**2014**:284172.
197. Barold SS, Falkoff MD, Ong LS, Heinle RA. Hyperkalemia-induced failure of atrial capture during dual-chamber cardiac pacing. *J Am Coll Cardiol* 1987;**10**:467–9.
198. Kahloun MU, Aslam AK, Aslam AF, Wilbur SL, Vasavada BC, Khan IA. Hyperkalemia induced failure of atrial and ventricular pacemaker capture. *Int J Cardiol* 2005;**105**:224–6.
199. Boriani G, Rusconi L, Biffi M, Pavia L, Sassara M, Malfitano D *et al*. Role of ventricular autocapture function in increasing longevity of DDDR pacemakers: a prospective study. *Europace* 2006;**8**:216–20.
200. Tan CS, Jie C, Joe J, Irani ZD, Ganguli S, Kalva SP *et al*. The impact of transvenous cardiac devices on vascular access patency in hemodialysis patients. *Semin Dial* 2013;**26**:728–32.
201. Cannizzaro LA, Piccini JP, Patel UD, Hernandez AF. Device therapy in heart failure patients with chronic kidney disease. *J Am Coll Cardiol* 2011;**58**:889–96.
202. Heywood JT, Fonarow GC, Yancy CW, Albert NM, Curtis AB, Stough WG *et al*. Influence of renal function on the use of guideline-recommended therapies for patients with heart failure. *Am J Cardiol* 2010;**105**:1140–6.
203. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L *et al*. The effect of cardiac resynchronization on morbidity and mortality in heart failure. *N Engl J Med* 2005;**352**:1539–49.
204. Shalaby A, El-Saed A, Voigt A, Albany C, Saba S. Elevated serum creatinine at baseline predicts poor outcome in patients receiving cardiac resynchronization therapy. *Pacing Clin Electrophysiol* 2008;**31**:575–9.
205. van Bommel RJ, Borleffs CJ, Ypenburg C, Marsan NA, Delgado V, Bertini M *et al*. Morbidity and mortality in heart failure patients treated with cardiac resynchronization therapy: influence of pre-implantation characteristics on long-term outcome. *Eur Heart J* 2010;**31**:2783–90.
206. Goldenberg I, Moss AJ, McNitt S, Barsheshet A, Gray D, Andrews ML *et al*. Relation between renal function and response to cardiac resynchronization therapy in Multicenter Automatic Defibrillator Implantation Trial—Cardiac Resynchronization Therapy (MADIT-CRT). *Heart Rhythm* 2010;**7**:1777–82.
207. Lin G, Gersh BJ, Greene EL, Redfield MM, Hayes DL, Brady PA. Renal function and mortality following cardiac resynchronization therapy. *Eur Heart J* 2011;**32**:184–90.
208. Mathew J, Katz R, St John Sutton M, Dixit S, Gerstenfeld EP, Ghio S *et al*. Chronic kidney disease and cardiac remodeling in patients with mild heart failure: results from the RESynchronization reVERSes Remodeling in Systolic Left vEntricular Dysfunction (REVERSE) study. *Eur J Heart Fail* 2012;**14**:1420–8.
209. Friedman DJ, Upadhyay GA, Singal G, Orencole M, Moore SA, Parks KA *et al*. Usefulness and consequences of cardiac resynchronization therapy in dialysis-dependent patients with heart failure. *Am J Cardiol* 2013;**112**:1625–31.
210. Hosoda J, Ishikawa T, Matsushita K, Matsumoto K, Kimura Y, Miyamoto M *et al*. Impact of renal insufficiency on long-term clinical outcome in patients with heart failure treated by cardiac resynchronization therapy. *J Cardiol* 2012;**60**:301–5.
211. Garg N, Thomas G, Jackson G, Rickard J, Nally JV Jr, Tang WH *et al*. Cardiac resynchronization therapy in CKD: a systematic review. *Clin J Am Soc Nephrol* 2013;**8**:1293–303.
212. Korantzopoulos P, Liu T, Li L, Goudevenos JA, Li G. Implantable cardioverter defibrillator therapy in chronic kidney disease: a meta-analysis. *Europace* 2009;**11**:1469–75.
213. Sakhuja R, Keebler M, Lai TS, McLaughlin Gavin C, Thakur R, Bhatt DL. Meta-analysis of mortality in dialysis patients with an implantable cardioverter defibrillator. *Am J Cardiol* 2009;**103**:735–41.
214. Hage FG, Aljaroudi W, Aggarwal H, Bhatia V, Miller J, Doppalapudi H *et al*. Outcomes of patients with chronic kidney disease and implantable cardiac defibrillator: primary versus secondary prevention. *Int J Cardiol* 2013;**165**:113–6.
215. Pun PH, Al-Khatib SM, Han JY, Edwards R, Bardy GH, Bigger JT *et al*. Implantable cardioverter-defibrillators for primary prevention of sudden cardiac death in CKD: a meta-analysis of patient-level data from 3 randomized trials. *Am J Kidney Dis* 2014;**64**:32–9.
216. Hess PL, Hellkamp AS, Peterson ED, Sanders GD, Al-Khalidi HR, Curtis LH *et al*. Survival after primary prevention implantable cardioverter-defibrillator placement among patients with chronic kidney disease. *Circ Arrhythm Electrophysiol* 2014;**7**:793–9.
217. Makki N, Swaminathan PD, Hanmer J, Olshansky B. Do implantable cardioverter defibrillators improve survival in patients with chronic kidney disease at high risk of sudden cardiac death? A meta-analysis of observational studies. *Europace* 2014;**16**:55–62.
218. Buiten MS, De Bie MK, Van Der Heijden AC, Rotmans JJ, Bootsma M, Marc Groeneweld JH *et al*. Chronic kidney disease and implantable cardioverter defibrillator related complications: 16 years of experience. *J Cardiovasc Electrophysiol* 2014;**25**:998–1004.
219. Eisen A, Suleiman M, Strasberg B, Sela R, Rosenheck S, Freedberg NA *et al*. Renal dysfunction and clinical outcomes of patients undergoing ICD and CRTD implantation: data from the Israeli ICD registry. *J Cardiovasc Electrophysiol* 2014;**25**:990–7.
220. Genovesi S, Porcu L, Luise MC, Riva H, Nava E, Stella A *et al*. Mortality, sudden death and indication for cardioverter defibrillator implantation in a dialysis population. *Int J Cardiol* 2015;**186**:170–7.
221. Williams ES, Shah SH, Piccini JP, Sun AY, Koontz JJ, Al-Khatib SM *et al*. Predictors of mortality in patients with chronic kidney disease and an implantable defibrillator: an EPGEN substudy. *Europace* 2011;**13**:1717–22.

222. Barshesht A, Moss AJ, Huang DT, McNitt S, Zareba W, Goldenberg I. Applicability of a risk score for prediction of the long-term (8-year) benefit of the implantable cardioverter defibrillator. *J Am Coll Cardiol* 2012;**58**:2075–9.
223. Amin MS, Fox AD, Kalahasty G, Shepard RK, Wood MA, Ellenbogen KA. Benefit of primary prevention implantable cardioverter-defibrillators in the setting of chronic kidney disease: a decision model analysis. *J Cardiovasc Electrophysiol* 2008;**19**:1275–80.
224. Lambiase PD, Barr C, Theuns DA, Knops R, Neuzil P, Johansen JB et al. Worldwide experience with a totally subcutaneous implantable defibrillator: early results from the EFFORTLESS S-ICD registry. *Eur Heart J* 2014;**35**:1657–65.
225. Klein HU, Goldenberg I, Moss AJ. Risk stratification for implantable cardioverter defibrillator therapy: the role of the wearable cardioverter-defibrillator. *Eur Heart J* 2013;**34**:2230–42.
226. Saad TF, Hentschel DM, Koplan B, Wasse H, Asif A, Patel DV et al. Cardiovascular implantable electronic device leads in CKD and ESRD patients: review and recommendations for practice. *Semin Dial* 2013;**26**:114–23.
227. Saad TF, Ahmed W, Davis K, Jurkovic C. Cardiovascular implantable electronic devices in hemodialysis patients: prevalence and implications for arteriovenous hemodialysis access interventions. *Semin Dial* 2015;**28**:94–100.
228. Drew DA, Meyer KB, Weiner DE. Transvenous cardiac device wires and vascular access in hemodialysis patients. *Am J Kidney Dis* 2011;**58**:494–6.
229. Charytan DM, Patrick AR, Liu J, Setoguchi S, Herzog CA, Brookhart MA et al. Trends in the use and outcomes of implantable cardioverter-defibrillators in patients undergoing dialysis in the United States. *Am J Kidney Dis* 2011;**58**:409–17.
230. Diemberger I, Biffi M, Martignani C, Boriani G. From lead management to implanted patient management: indications to lead extraction in pacemaker and cardioverter-defibrillator systems. *Expert Rev Med Devices* 2011;**8**:235–55.
231. De Maria E, Diemberger I, Vassallo PL, Pastore M, Giannotti F, Ronconi C et al. Prevention of infections in cardiovascular implantable electronic devices beyond the antibiotic agent. *J Cardiovasc Med (Hagerstown)* 2014;**15**:554–64.
232. Greenspon AJ, Patel JD, Lau E, Ochoa JA, Frisch DR, Ho RT et al. 16-year trends in the infection burden for pacemakers and implantable cardioverter-defibrillators in the United States 1993 to 2008. *J Am Coll Cardiol* 2011;**58**:1001–6.
233. Polyzos KA, Konstantelias AA, Falagas ME. Risk factors for cardiac implantable electronic device infection: a systematic review and meta-analysis. *Europace* 2015;**17**:767–77.
234. Mittal S, Shaw RE, Michel K, Palekar R, Arshad A, Musat D et al. Cardiac implantable electronic device infections: incidence, risk factors, and the effect of the AigisRx antibacterial envelope. *Heart Rhythm* 2014;**11**:595–601.
235. Deharo JC, Quatre A, Mancini J, Khairy P, Le Dolley Y, Casalta JP et al. Long-term outcomes following infection of cardiac implantable electronic devices: a prospective matched cohort study. *Heart* 2012;**98**:724–31.
236. Hickson LJ, Gooden JY, Le KY, Baddour LM, Friedman PA, Hayes DL et al. Clinical presentation and outcomes of cardiovascular implantable electronic device infections in hemodialysis patients. *Am J Kidney Dis* 2014;**64**:104–10.
237. Kato S, Chmielewski M, Honda H, Pecoits-Filho R, Matsuo S, Yuzawa Y et al. Aspects of immune dysfunction in end-stage renal disease. *Clin J Am Soc Nephrol* 2008;**3**:1526–33.
238. Tompkins C, McLean R, Cheng A, Brinker JA, Marine JE, Nazarian S et al. End-stage renal disease predicts complications in pacemaker and ICD implants. *J Cardiovasc Electrophysiol* 2011;**22**:1099–104.
239. Asif A, Salman L, Lopera G, Haqqie SS, Carrillo R. Transvenous cardiac implantable electronic devices and hemodialysis catheters: recommendations to curtail a potentially lethal combination. *Semin Dial* 2012;**25**:582–6.
240. Baddour LM, Epstein AE, Erickson CC, Knight BP, Levison ME, Lockhart PB et al. Update on cardiovascular implantable electronic device infections and their management: a scientific statement from the American Heart Association. *Circulation* 2010;**121**:458–77.
241. Diemberger I, Mazzotti A, Giulia MB, Cristian M, Matteo M, Letizia ZM et al. From lead management to implanted patient management: systematic review and meta-analysis of the last 15 years of experience in lead extraction. *Expert Rev Med Devices* 2013;**10**:551–73.
242. Asif A, Carrillo R, Garisto JD, Monrroy M, Khan RA, Castro H et al. Prevalence of chronic kidney disease in patients undergoing cardiac rhythm device removal. *Semin Dial* 2013;**26**:111–3.
243. Crossley GH, Poole JE, Rozner MA, Asirvatham SJ, Cheng A, Chung MK et al. The Heart Rhythm Society (HRS)/American Society of Anesthesiologists (ASA) Expert Consensus Statement on the perioperative management of patients with implantable defibrillators, pacemakers and arrhythmia monitors: facilities and patient management this document was developed as a joint project with the American Society of Anesthesiologists (ASA), and in collaboration with the American Heart Association (AHA), and the Society of Thoracic Surgeons (STS). *Heart Rhythm* 2011;**8**:1114–54.
244. Braunschweig F, Boriani G, Bauer A, Hatala R, Herrmann-Lingen C, Kautzner J et al. Management of patients receiving implantable cardiac defibrillator shocks: recommendations for acute and long-term patient management. *Europace* 2010;**12**:1673–90.
245. Manegold JC, Israel CW, Ehrlich JR, Duray G, Pajitnev D, Wegener FT et al. External cardioversion of atrial fibrillation in patients with implanted pacemaker or cardioverter-defibrillator systems: a randomized comparison of monophasic and biphasic shock energy application. *Eur Heart J* 2007;**28**:1731–8.
246. Nazarian S, Roguin A, Zviman MM, Lardo AC, Dickfeld TL, Calkins H et al. Clinical utility and safety of a protocol for noncardiac and cardiac magnetic resonance imaging of patients with permanent pacemakers and implantable-cardioverter defibrillators at 1.5 tesla. *Circulation* 2006;**114**:1277–84.
247. St Peter WL. Introduction: chronic kidney disease: a burgeoning health epidemic. *J Manag Care Pharm* 2007;**13**(9 Suppl D):S2–5.
248. Vanholder R, Davenport A, Hannedouche T, Kooman J, Kribben A, Lameire N et al. Reimbursement of dialysis: a comparison of seven countries. *J Am Soc Nephrol* 2012;**23**:1291–8.
249. Boriani G, Maniadakis N, Auricchio A, Müller-Riemenschneider F, Fattore G, Leyva F et al. Health technology assessment in interventional electrophysiology and device therapy: a position paper of the European Heart Rhythm Association. *Eur Heart J* 2013;**34**:1869–74.
250. Maniadakis N, Vardas P, Mantovani LG, Fattore G, Boriani G. Economic evaluation in cardiology. *Europace* 2011;**13**(Suppl 2):ii3–8.
251. Fattore G, Maniadakis N, Mantovani LG, Boriani G. Health technology assessment: what is it? Current status and perspectives in the field of electrophysiology. *Europace* 2011;**13**(Suppl 2):ii49–53.
252. Boriani G, Diemberger I, Biffi M, Martignani C. Cost-effectiveness of cardiac resynchronization therapy. *Heart* 2012;**98**:1828–36.
253. Arribas F, Auricchio A, Boriani G, Brugada J, Deharo JC, Hindriks G et al. Statistics on the use of cardiac electronic devices and electrophysiological procedures in 55 ESC countries: 2013 report from the European Heart Rhythm Association (EHRA). *Europace* 2014;**16**(Suppl 1):i1–78.
254. Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B et al. Chronic kidney disease: global dimension and perspectives. *Lancet* 2013;**382**:260–72.
255. Clarkesmith DE, Pattison HM, Lip GY, Lane DA. Educational intervention improves anticoagulation control in atrial fibrillation patients: the TREAT randomized trial. *PLoS ONE* 2013;**8**:e74037.
256. Boriani G, Diemberger I, Martignani C, Biffi M, Valzania C, Bertini M et al. Telecardiology and remote monitoring of implanted electrical devices: the potential for fresh clinical care perspectives. *J Gen Intern Med* 2008;**23**(Suppl 1):73–7.
257. Boriani G, Da Costa A, Ricci RP, Quesada A, Favale S, Iacopino S et al. The MOonitoring Resynchronization dEVICES and CARdiac patiEnts (MORE-CARE) randomized controlled trial: phase 1 results on dynamics of early intervention with remote monitoring. *J Med Internet Res* 2013;**15**:e167.
258. Boriani G. Remote monitoring of cardiac implantable electrical devices in Europe: quo vadis? *Europace* 2015;**17**:674–6.